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Heart disease is the number one killer in the United States.  Within this sector, valve 
disease plays a very important role:  Approximately 6% of the entire population has 
either prolapse or stenosis of the mitral valve and this percentage only increases when 
looking only at the elderly population.  Transapical mitral valve implantation has 
promised to be a potential therapy for high-risk patients presenting with MR; however it 
is unclear what the best method of securing a valve within the mitral annulus may be to 
provide a safe and efficient valve replacement. 
The objective of this research is to study and understand the underlying biomechanics 
of fixation of transapical mitral valves within the native mitral annulus.  Two different 
transapical mitral valve prosthesis designs were tested:  One valve design has a portion 
of the leaflets atrialized such that it has a shorter stent height and the valve itself sits 
within the native annulus, the other design is not atrialized and protrudes further into the 
left ventricle.  The valves were implanted in a left heart simulator to assess leaflet 
kinematics and hemodynamics using high speed imagery and particle image 
velocimetry techniques.  An in vitro passive beating heart model was then used to 
assess the two different fixation methods (namely, anchored at the apex vs. anchored at 
the annulus) with respect to paravalvular regurgitation.  Leaflet kinematics and 
hemodynamics revealed proper leaflet coaptation and acceptable pressure gradients 
and inflow fillings; however, both designs yielded elevated turbulence stresses within 
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the ventricle.  At 60 beats per minute, leaflet opening and closing times were both under 
0.1 seconds, max Reynolds shear stresses were between 40 and 60 N/m2 and 
maximum velocities were approximately 1.4 m/s.  Assessment of the different fixation 
methods during implantation revealed the superiority of the atrialized valve when 
anchored at the annulus (p<0.05), but showed no such comparison during tethered 
implantation.  In addition to the results of statistical testing, observations show that the 
importance of the relationship between ventricular stent height and fixation method 
compared with native anatomy plays an important role in overall prosthesis function 
regardless of implantation method.  
iv 
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Heart disease is the leading cause of death in the United States, causing nearly 1 in 
every 4 deaths (CDC, 2010).  Within heart disease there are many subcategories of 
diseases that affect the heart, these include:  coronary artery disease, valve disease, 
congenital heart defects and many others.  Valve disease is one category that places a 
large burden on the medical system.  It is estimated that 2.5% of the population of the 
United States have been diagnosed with valve disease and the prevelance of mitral 
valve disease is nearly double that of aortic valve disease (AHA, 2014). Treatment of 
aortic valve diseases has seen the development of percutaneous valve replacements 
(transcatheter aortic valve implantation, TAVI), but this technhology has not yet made its 
way to mitral valve replacements yet.  Given the high prevalence of mitral valve disease 
and the increasingly elderly patient population that presents with this disease, there is a 
great need for minimally invasive mitral valve therapies.  Several percutaneous repair 
strategies have been developed with the Mitraclip device being one of the most 
successful on the clinical stage.  The device is designed to result in a mitral repair 
based on the Alfieri edge-to-edge technique and has reported the results of clinical trials 
[1]; however, due to the complexity of the anatomy of atrio-ventricular valves, 
perctuaneous mitral valve replacement has yet to see clinical trials. 
Preclinical animal studies of various trans-apical mitral valve implantation  (TAMI) valve 
prototypes have seen some success; with several seeing first-in-man implantations.  
However, no studies (animal or in vitro) have been undertaken to truly understand the 
biomechanics of various methods of fixing TAMI valves within the mitral annulus.  
2 
Valves implanted within the mitral annulus cannot rely on radial force to anchor them as 
seen in their aortic counterparts.  For this reason, valves must contain a method to 
secure them on both the atrial and ventricular sides of the atrioventricular junction.  
Typically, an atrial skirt is used that hugs the atrial floor and prevents the valve from 
migrating into the left ventricle.  On the ventricular side, there are two prominent means 
of fixation:  Tethering and hooking.  Tethered impantation mimics the native chords and 
uses a series of tehters attached to the valve stent that are then anchored at the apex of 
the heart to prevent valve migration.  The other method of implantation, hooking, uses a 
series of hooks that grasp onto the native valve tissue.  The hooks typically grab onto a 
combination of mitral valve leaflet and chordae tendinae to keep the valve in place.  
There are many factors that must be considered when picking a certain fixation method:  
ventricular remodeling, myocardial dynamics, varying anatomy between patients, ease 
of orientation and deployment, and many others.   
While a benchtop model can only begin to approach answering the question for some of 
these considerations, it is a start that can hone the focus when moving on to animal 
studies.  In addition, animal studies are both very costly and very time-consuming.  
Studying newly developed prosthetic valves in an accurate in-vitro simulator can result 
in a  quicker pipeline to clinical trials and application to patients. 
It is the aim of this research to apply engineering principles to the documentation of  the 
biomechanics of varying ventricular fixation methods of TAMI valves and their related 
effect on paravalvular leakage. 
3 
This study will begin with standard study of the hemodynamics and mechanics of 
several TAMI valves in an ideal left heart simulator and move to an in-vitro beating heart 
simulator utilizing porcine hearts to assess varying fixation methods and they’re effects 
on mitral valve competence. 
1.1 Aims and Hypotheses  
1.1.1 Aim 1 
Aim 1:  Evaluate leaflet kinematics and flow through each of two valve designs using a 
left heart simulator and Particle Image Velocimetry (PIV) 
Hypothesis 1:  Valve mechanics and hemodynamics will results in flows that adequately 
resemble physiologic conditions 
A left heart simulator will be used to test each of two valve designs.  The left heart 
simulator utilizes a clear, acrylic block to simulate a left ventricle and house the valves.  
This clear block allow for high speed imaging of the valve leaflets to assess leaflet 
kinematics and also allows for particle image velocimetry (PIV) to be performed to 
assess the fluid mechanics through the valves.  The data gathered from performing PIV 
will be used to determine vorticity, maximum velocities, and Reynolds shear stresses. 
1.1.2 Aim 2 
Aim 2:  Evaluate and understand the difference in mechanics between two different 
methods of ventricular fixation for transapical mitral valves. 
Hypothesis 2:  Due to the variability of native mitral valve tissue, tethering will prove be 
a superior option for ventricular fixation. 
4 
An in-vitro beating heart simulator will be used to artificially create a beating heart using 
pressurized fluid and a porcine heart.  Two different transapical mitral valve designs will 
be implanted in two different fashions each:  tethered and sutured.  The resulting 
paravalvular regurgitation in each of the conditions will be measured using multiple flow 
probes.  Pressure taps and cardiac Doppler imaging will also be used to assess valve 
function. 
1.2 Organization 
Chapter 2 will contain a literature review of information pertaining to this research.  
Following this will be a chapter for each of the Aims of this research.  Each chapter will 
contain both the methodology and results for each aim.  The methodologies used in 
each aim are vastly different and thus do not appear in a single methods chapter.  In the 
chapter for each aim, the results and discussion will also occur simultaneously in a 
single section.  Following these chapters will be a summary of the findings as well as a 
discussion of the limitations for each aim.  
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2.1 The Heart 
The heart is a muscular organ that generates the force necessary to deliver blood to the 
entire body.  The heart consists of four separate chambers:  two upper chambers known 
as atria and two lower chambers known as ventricles.  The ventricles are the chambers 
that work to deliver blood through both the pulmonary and systemic circuits.  The heart 
can be subdivided into two distinct sides:  the right side receives blood from the 
systemic circuit and sends blood to the lungs to be oxygenated while the left side 
receives oxygenated blood from the pulmonary circuit and sends it to the rest of the 
body.  The left side has to generate a significantly greater amount of force to deliver 
blood to the entire systemic circuit and thus occupies a much larger portion of the heart 
and contains a much thicker myocardium [2]. 
There are four valves found in the heart:  the pulmonary valve, aortic valve, tricuspid 
valve and mitral valve.  The two former exist at the beginning of major arteries leaving 
the heart (pulmonary artery and the aorta) while the two later exist in the atrioventricular 
junction:  The tricuspid valve sits between the right atrium and the right ventricle and the 
mitral valve sits between the left atrium and the left ventricle. 
2.2 The Mitral Valve 
2.2.1 Anatomy and Mechanics 
Proper mechanics of the mitral valve (MV) are the result of a complex interaction 
between four components whose main goal is to prevent the backflow of blood from the 
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left ventricle into the left atrium during systole, but allowing such flow during diastole.  
These four components are the annulus, leaflets, chordae tendinae and papillary 
muscles.  Figure 1 illustrates the anatomic relationship of each of these four 
components. 
In the MV it is that valve leaflets that are 
ultimately responsible for preventing regurgitant 
blood flow.  The MV is a bileaflet valve 
consisting of the anterior (aortic) and posterior 
(mural) leaflets.  The leaflets are asymmetric in 
shape, but have nearly identical surface areas.  
Both of the leaflets are part of a continuous band 
of tissue anchored to the mitral annulus at the 
base and to the chordae tendinae at their free 
edge.  They are indented at two points and these 
indentations are known as commissures.  The 
commissures divide this continuous band of tissue into two distinct leaflets for proper 
opening during diastole and they also aid in proper leaflet coaptation during systole [3].  
In adults, the posterior leaflet has indentations that typically divide the leaflet into three 
scallops, or segments, along the free edge:  These scallops are labeled as P1, P2 and 
P3.  The anterior leaflet also has similar labeling, however, it is arbitrarily segmented as 
A1, A2, and A3 corresponding to the adjacent posterior leaflet scallop [4].  These 
designations can be seen in Figure 2.  The leaflet designations are also important 
landmarks when measuring the septo-lateral (anteroposterior diameter) of the mitral 
 
Figure 1.  The anatomical relationship of 
the primary components of the mitral 
valve:  mitral valve leaflets, chordae 
tendinae and the papillary muscles. 
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annulus.  This diameter is the annulus diameter measured from the center of A2 to the 
center of P2.  The beginning and end points of this measurement are where the leaflets 
integrate with the mitral annulus.  The second important annulus diameter is the 
commissure-commissure diameter.  This measurement is as the name implies, the 
distance between the two commissures. 
Although the mitral annulus is what 
physically separates the left atrium from the 
left ventricle, it is not visible from the atrium 
as it is deeper and roughly 2mm external to 
the visible hinge of the leaflets [3].  The 
annulus itself takes what is known as a ‘D’ 
shape and is conventionally divided into both 
posterior and anterior portions.  The anterior 
portion contains the anterior leaflet and is also anatomically coupled to the aortic 
annulus.  The posterior portion encompasses the rest (larger portion) of the mitral 
annulus and is composed of fibrous tissue periodically interrupted by fat.  The 
discontinuous nature of the fibrous tissue is thought to be why the posterior annulus 
experiences more enlargement than the anterior [5].  Enlargement of the mitral annulus 
is of great consequence on the performance of the MV. 
The mitral annulus is uniquely situated very near to myocardial fibers of the heart.  This 
causes the geometry of the mitral annulus to change throughout the cardiac cycle.  
During systole, the area of the mitral annulus is asymmetrically reduced and takes the 
shape of a three dimensional saddle.  This reduces the area that the mitral leaflets must 
 
Figure 2.  The geometry of the mitral leaflets 
as well as the labeling convention for the 
varying regions of the leaflets can be seen 
above [3]. 
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cover and increases the leaflet area available for proper coaptation  [3].  This motion 
that the annulus undergoes is known as annular folding and is theorized to be caused 
by several mechanisms.  During ventricular contraction, the entire mitral annulus is 
translated apically; however, due to the inconsistent anatomical composition of the 
annulus, the anterior and posterior portions translate differently.  This results in a folding 
of the annulus along the intercommissural axis [5].  These dynamics and three 
dimensionality are illustrated in Figure 3. This figure also shows the altered annular 
motion and shape associated with a common degenerative disease affecting the mitral  
 
Figure 3.   Illustrates the dynamics and three dimensionality of the mitral annulus between systole 
(B, D) and diastole (A, C).  A and B are normal functioning mitral valves.  C and D show the altered 
dynamics of the mitral annulus with Myxomatous Degeneration.  Myxomatuous Degeneration 
refers to a pathological weakening of the body’s connective tissue [5].  
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valve, myxomatous degeneration.  Myxomatous degeneration refers to a weakening of 
the body’s connective tissue is often associated with a prolapsed mitral valve.   
The chordae tendinae (CT) and papillary muscles (PM) act as a suspension system for 
the mitral valve.  They facilitate leaflet opening during diastole and prevent the leaflets 
from migrating toward the left atrium during systole.  The CT primarily attach the mitral 
valve leaflets to a PM imbedded in the ventricular wall, however, in some cases the CT 
attach directly to the ventricular wall.  There is a hierarchy of CT structure and function 
with a variety of sizes, shapes and bifurcations.  A dissected example of the CT, PM 
complex can be seen in Figure 4.   
 
Figure 4.  The complex hierarchy of the chordae tendinae and their anatomical positioning 
between the papillary muscles and mitral valve leaflets [4]. 
 
The PMs function to adjust tension on the CT throughout the cardiac cycle.  There are 
typically two groups of papillary muscles attached to the ventricular wall.  The naming 
convention is based on their position relative to the two mitral leaflet commissures:  
anterolateral and posteromedial.  It has been shown that papillary muscles maintain 
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their distance from the mitral annulus throughout the entire cardiac cycle:  Thus, 
contracting during systole and elongating during diastole.  From this observation, it has 
been hypothesized that the papillary muscle, chordae tendinae complex act as shock 
absorbers that maintain the geometric shape of the mitral valve throughout the cardiac 
cycle [6]. 
2.2.2 Valve Disease 
The mitral valve is arguably the most complex of all the valves in the human heart and 
is also happens to be the most commonly diseased.  Typical mitral valve conditions are 
stenosis, regurgitation, and leaflet prolapse; ranking in order of commonality with 
stenosis being the least prevalent and leaflet prolapsed being the most prevalent.  Its 
estimated that up to 5% of the population presents with mitral leaflet prolapsed, while 
1% experience mitral stenosis [7]. 
Stenosis, or obstruction of the mitral valve, can have several causes.  One of these 
causes is rheumatic fever; however, the availability of antibiotics in developed countries 
has all be eradicated this cause, but it is important to note that this is still relatively 
common disease in developing countries.  Another more common cause of mitral 
stenosis is calcified valve leaflets often seen in elderly patients.  Stenosis leads to an 
insufficient amount of blood flow during diastole causes a larger portion of blood to 
remain in the left atrium.  This can result in left atrium stretch and resulting blockage of 
the cardiac electrical pathways which leads to irregular heartbeats and resulting 
palpitations [7]. 
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Mitral regurgitation (MR), or valve leakage, occurs when the mitral valve does not close 
completely during systole (contraction of the left ventricle).  When this occurs, blood 
returns into the left atrium instead of proceeding to systemic circulation.  Causes of MR 
are divided into two different categories:  organic and functional.  Organic MR occurs 
when there is a problem with the mitral valve apparatus itself that results in MR.  
Organic MR can further be broken down into rheumatic (resulting from rheumatic fever) 
and degenerative MR.  Degenerative MR primarily presents itself as a prolapse of one 
or both of the mitral valve leaflets.  Functional MR occurs when regurgitation is 
secondary to a disease of the left ventricle.  Function MR is typically caused either by 
ischemia or some other cause of dilation of the left ventricle.  The enlargement of the 
left ventricle can either result in a stretching of the mitral annulus or excessive tethering 
forces being placed on the chordate tendinae, both of which lead to poor leaflet 
coaptation. 
2.3 Heart Valve Interventions 
2.3.1 Treatment of Valve Disease 
A faulty mitral valve can be treated with one of two methods:  replacing the faulty valve 
or repairing it.  There exist many different repair options for mitral valves including, but 
not limited to: leaflet resection, balloon valvuloplasty, annuloplasty ring implantation, 
edge-to-edge repair and neo-chordae implant.  There also exist nearly as many options 
for valve replacement.  An abundance of companies produce commercially available 
and FDA and CE approved mitral valve prostheses.  Since the first implanted heart 
valve in 1952, upwards of 50 different heart valve designs have been developed and in 
2009 nearly three million have been implanted worldwide [8].  
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Although there is some debate as to which method of mitral valve treatment is superior, 
several studies have recently shown the non-inferiority of mitral valve replacement as a 
treatment.  A recent, randomized study by the NIH reported severe ischemic MR patient 
outcomes between valve repair and replacement:  Patients were randomized between 
valve annuloplasty and valve repair.  After a 24 month follow up, there were no health 
outcomes between groups; the only significant difference was a 32.6% chance of 
recurrent MR in the repair group versus 3.2% in the replacement group; although this 
recurrent MR did not lead to any noticeable health problems in the repair group over the 
course of the study [9].   
A significant portion of the patient population that experiences mitral regurgitation is 
elderly:  The American Heart Association reports that of all patients aged 75 and above, 
10% present with some form of mitral regurgitation [10].  Many patients – especially 
these elderly patients previously mentioned – present with significant co morbidities or 
left ventricular dysfunction that is severe enough such that they are not referred for 
conventional surgical treatment [11].  Because of this large patient population that is 
unable to go through conventional open heart surgery, it is becoming more and more 
important to develop minimally invasive interventions for MR. 
2.3.2 Minimally Invasive Interventions 
The large draw for minimally invasive interventions is the reduced surgical trauma 
experienced by the patient.  This reduced trauma results in a significantly reduced 
recovery time as well as a much lower peri-operative risk.  This reduced risk is a 
necessity for high-risk patients to be eligible for the therapy.  Figure 5 shows the 
comparative invasiveness of open heart surgery compared to two minimally invasive 
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options.  The two images on the left show a transfemoral and transapical insertion 
respectively with the image on the right being a standard open heart procedure.  During 
a transfemoral implantation, a catheter based delivery system is used to deliver the 
prosthesis to the heart via the femoral artery.  Transapical implants use a small incision 
to access the apex of the heart and deliver the prosthesis. 
 In a study looking at patients with 
severe aortic stenosis, more than 
30% of the patients were deemed 
ineligible for conventional aortic 
valve replacement surgery because 
of multiple co-morbidities [12].  
Though this statistic focuses on 
inoperable patients with aortic valve 
disease, a similar analogue can be 
seen in the mitral valve:  As quoted 
previously, of all patients 75 and 
above, 10% present with present 
with MR [10].  With this increase in age comes an increase in co-morbidities and high 
surgical risk, which results in many of these patients not being recommended for 
conventional mitral valve replacement. 
2.3.3 Transcatheter Aortic Valve Implantation 
Although not suitable for native mitral valve dysfunction, the first trans-catheter aortic 
valve implantation (TAVI) was introduced in 2002.  Since initial approvals in Europe in 
 
Figure 5.  Comparison of minimally invasive 
interventions and the conventional open heart 
approach.  A and B show transfemoral and 
transapical approaches respectively while C is a 
conventional open heart surgery (Edwards 
Lifesciences). 
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2007, a significant number of inoperable patients have undergone a TAVI procedure 
(estimates from 2011 put that number at greater than 20,000).  There are currently two 
commercially available TAVI valves in the United States:  Edwards Sapien and 
Medtronic Corevalve [13].  These valves – seen in Figure 6– are typically implanted via 
the femoral artery or apex of the heart and either balloon expanded or self expanded 
into the native aortic valve.  Clinical results of TAVI show much promise, with most 
results showing increased long term outcomes of patients receiving this procedure [14, 
15].   
 
Figure 6.  Two examples of TAVI valves.  The Medtronic Corevalve can be seen on the left and the 
Edwards Sapien can be seen on the right. 
TAVI valves are designed to utilize their radial force to maintain their position within the 
very cylindrical aortic root.  Given the lack of uniformity within the native mitral annulus, 
these valves are not suitable for implantation in the mitral position; however, there has 
been some clinical success with implanting these TAVI valves within failing 
bioprosthesis in the mitral position [16-18].  In addition, there have been several 
reported cases of TAVI valve-in-annuloplasty ring implantations [18-20].  Although there 
has been some success in expanding the potential for TAVI implantation, there have 
15 
been relatively few minimally invasive interventions developed with the mitral valve 
apparatus as the primary target [17]. 
2.3.4 Minimally Invasive Mitral Repair 
In recent years, several percutaneous mitral repair technologies have emerged and are 
at various levels of development.  These percutaneous technologies include:  edge-to-
edge repair, annuloplasty, and chordal implant.  One of the select few of these 
technologies, Mitraclip – a percutaneous intervention based on the Alfieri technique, 
seen in Figure 7– has presented the results of a randomized clinical trial and thus far 
appears to be a reasonable option for a select group of patients [11].  In practice, 
however, the Mitraclip implantation has been a very difficult procedure requiring a very 
experienced medical team. 
 
2.3.5 Trans Apical Mitral Valve Implantation (TAMI) 
In addition to these repair technologies, several research groups have begun pre-
clinical animal studies of minimally invasive mitral valve replacements; to date, there 
have also been two in man implantations of TAMI valves.  Compared to TAVI 
procedures, the mitral valve apparatus presents a much more complicated geometry 
 
Figure 7.  Abbott Laboratories has developed Mitraclip, a percutaneous method to implement an 
edge-to-edge mitral repair technique (Abbott Laboratories). 
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and approach.  Firstly, it has been shown that leaving the native mitral apparatus intact 
is important in retaining proper left ventricular geometry and function [21].  This means 
that mitral implant design must take into account the native anatomy of the mitral 
apparatus and leave it as undisturbed as possible.  Also, due to the asymmetry, lack of 
rigidity and dynamics of the native mitral annulus; TAMI valves cannot rely on radial 
force for secure attachment within the native mitral annulus as has been seen in aortic 
and pulmonary valve replacements.  Any attempt at using radial force to anchor the 
prosthesis can have deleterious effects:  obstruction of the left ventricular outflow tract 
(LVOT), systolic anterior motion (SAM), valve migration into either the left atrium or left 
ventricle, distortion of the native annulus and its dynamics, compression of the adjacent 
coronary circumflex artery, and impingement of the conducting systems of the heart [22, 
23]. 
There have been several solutions proposed for valve fixation without using radial force.  
Two different options appear to be the most common among valves undergoing pre 
clinical trials:  tethering the valve to the apex of the heart as seen in the native mitral 
apparatus and hooking onto the native mitral valve tissue (chordae tendinae and native 
leaflets) to anchor the valve in place [22-29]. 
The first experimental study in the field of minimally invasive atrioventricular valve 
replacement was published in 2004 [30].  Since this first publication, several more 
research groups have published their own animal studies on their own uniquely 
developed valve devices.  To date, two in-man implantations of minimally invasive mitral 
bioprosthesis have occurred.  First in man was claimed by CardiAQ Valve 
Technologies, Inc. in June of 2012 as a compassionate treatment for an elderly man 
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experiencing severe MR.  The second implantation was conducted using the Tiara 
mitral valve developed by Neovasc, Inc.  The implant – occurring in January of 2014 – 
was uneventful and no adverse events were reported at least two months post op.  
Although Neovasc Inc. has published preclinical animal studies, CardiAQ Valve 
Technologies has released no results of any of their preclinical studies.  In addition to 
CardiAQ, there are several other minimally invasive mitral prostheses being developed 
privately; thus the status of their development nor any preclinical results can be 
discussed in any length. 
In the following section, the valve design and preclinical results for all published 
research will be discussed.  
2.3.6 Current Trans Apical Mitral Implantation Research 
In 2004 Liang Ma and colleagues implanted a double crowned design in adult swine 
[30].  In this publication, the surgeon implanted the valves via 
an incision in the left atrium instead of the apex of the heart.  
An image of the valve used by Ma et al can be seen in Figure 
8.  The native annulus sits in between the two nitinol ‘crowns’ 
in the stent body in order to prevent valve migration.  The 
animals survived no more than 3 hours post implantation; 
postmortem evaluation was conducted to confirm that the 
native annulus was in between the two ‘crowns’ of the stent body.  Three of the eight 
swine implanted showed mild paravalvular leakage (PVL), but it was determined that 
the source of this was annulus, prosthesis size mismatch:  The native annulus was, in 
 
Figure 8.  Double 
crowned stent designed 
by Ma and 
colleagues[30] 
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each case, at least 20% larger than the stent size.  No fracture of the valve stent was 
observed; however valve migration into the left ventricle occurred in one animal, which 
resulted in complete LVOT obstruction.  The study was proof that valve implant in this 
position was feasible with further studies expected to test if the implantation will also be 
feasible in humans. 
In 2005, Boudjemline et al implanted a percutaneous tricuspid valve replacement [31].  
The geometry of the tricuspid valve varies from the MV; however, due to the 
atrioventricular position; the tricuspid valve contains the same complexities associated 
with percutaneous implantation of a mitral valve. The valve design used was similar to 
that reported by Ma and involved a tubular section flanked on both sides by a disc like 
structure.  One each of these discs was to be deployed into the right atrium and right 
ventricle of the sheep in order to prevent valve migration and ensure proper sealing of 
the stent body.  Boudjemline et al replaced the tricuspid valve in 8 ewes (4 in a chronic 
study and 4 in an acute study) with moderate success.  Of the four animals implanted 
acutely, one had maldeployment with the ventricular disc becoming ensnared in the 
native chordae of the right ventricle.  In the chronic portion of the study, three of the four 
animals possessed good hemodynamics and no sign of leakage during the 1 month 
follow up period.  The fourth of these animals had a stent fracture which resulted in a 
PTFE tear and subsequent severe paravalvular leakage. 
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Between 2008 and 2011 collaboration between the University of Wisconsin School of 
Medicine and the University Hospital Schleswig-Holstein has produced a series animal 
studies documenting their trials of various TAMI valves.  An example of an early design 
can be seen in Figure 9.   This design utilizes an atrial 
skirt as the atrial fixation method and, contrary to the 
previous publications, a tethered design for ventricular 
fixation.  The tethers are designed to be attached to the 
ventricular wall to prevent migration into the atrium 
during systole.  All iterations of these valves have  
resulted in no LVOT obstruction as well as no systolic 
anterior motion (SAM) cause by displacement of the 
native mitral valve tissue.   Early acute implantation 
studies by this group resulted in no to mild paravalvular 
leakage and no stent migration up to one hour post 
implantation [23, 29].  Later publications implanted and 
observed similar valves until animal death.  Early 
animal deaths (less than one week) were reported to be primarily the result of atrial 
stent mal-deployment, while late death (greater than one week) were mostly attributed 
to stent fixation failure:  Either fracture of the atrial springs or failure of the ventricular 
fixation device [22, 25, 27].  A more long term study was completed with follow ups for 
the animals reaching 2 months post implantation.  Again, the one early animal death 
noted was due to maldeployment of the atrial portion of the stent.  Only mild or trace MR 
was observed in the remaining animals with no valve migration; however two pigs were 
 
 
Figure 9.  Ventricular (top) and 
atrial (bottom) views of the 
prosthesis developed by a 
collaboration between the 
University of Wisconsin School 




reported to have fracture of the atrial springs, but this fracture did not appear to affect 
the performance of the valve.  Tissue ingrowth of the atrial element of the valve was 
seen to be 50% at 1 month post implantation and 70% at two months post implantation 
[26].  This tissue ingrowth can be seen in Figure 10.  The effects of this tissue in growth 
were not elaborated on further.  This valve has shown to create a successful seal with 
easily reproducible valve deployment.  
The Tiara valve developed by Neovasc Inc. has 
published both  acute and long term pre-clinical 
trials and has recently become the second 
transapical mitral valve to be implanted in man 
[32].  The Tiara has taken into account the ‘D’ 
shaped geometry of the native mitral valve.  As 
seen in Figure 11 the valve possess a ‘D’ shape, 
mirroring the native mitral annulus.  Similar to 
previous valves, the Tiara uses an atrial skirt to fix 
the atrial side of thes tent, but it utilizes a unique method of ventricular fixation.  The 
Tiara relies on a set of hooks that grasp the native mitral leaflets and hold the valve 
stent in place.   
 
Figure 10.  Tissue ingrowth of the 
atrial element of this prosthesis seen 
several months post implantation [26] 
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In the acute ovine model, implantation was performed on 36 sheep.  Implantation was 
successful in 29 of these animals; however, both the valve itself and the surgical 
methods were being perfected during the 
time period.  The unsuccesful cases were 
due to improper valve position (n=3), failure 
of ventricular fixation hooks to properly 
engage (n=2) and ventrcular fibrillation 
(n=2).  None of the successfully implanted 
animals showed any LVOT obstruction and 
only animals with a sigificant mismatch 
between the annulus and valve size 
showed significant PVL.  In the acute 
model, the animals were monitored for a maximum of 96 hours before they were 
sacrificed.   
In the chronic model, seven sheep were implanted and monitored for approximately 150 
days.  All 7 animals were clinically stable and showed normal behavior throughout the 
entire follow-up period.  Two animals showed a mild degree of valvular MR and six 
animals had mild to moderate PVL.  None of the animals were shown to have LVOT 
obstruction and the left ventricle maintained normal size and function.  A view from the 
left atrium in the sacrificed pigs show that there is substantial fibrous tissue growth on 
the atrial skirt of the Tiara valve.  There was also a thin layer of growth along the 
ventricular surface of the valve as well.  The tissue growth on the atrial element can be 
seen in Figure 11.  A cadaveric study resulted in proper geometric positioning of the 
 
Figure 11.  The “D” shape of the Tiara is 
evident as well as the fibrous tissue growth 
on the atrial skirt.  View is from the left atrium 
of a sacrificed pig  [33]. 
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valve as well as proper engagement of both anchoring systems in all 24 hearts studied.  
These 24 hearts included both healthy and diseased hearts:  Of the diseased hearts, 
twelve had moderate to severe MR and 7 had congestive heart failure. 
In 2013 Gillespie and colleagues implanted a protoype transcatheter mitral valve in ten 
sheep in an acute ovine study [34].  An image of the prototype valve used in this study 
can be seen in Figure 12.  Contrary to what has been seen in the other studies, this 
valve utilizes an atrial hook system to grasp the supra-annular tissue and create a seal.  
The ventricular fixation mechanisms is similar to that seen in the Tiara valve.  This 
valve; however, utilizes a significantly greater number of hooks to grasp the native valve 
leaflets and chordae tendinae.  Details in the publication are scarce; however it appears 
that implantation was successful with no LVOT obstructution or paravalcular leakage 
reported.  It is important to note that the authors believed this to be merely a proof of 
concept for the valve and thus performed implantation utilizing cardiopulmonary bypass 
on the sheep.  The surgeons arrested the heart and performed the implantation through 
the left arium.  While this isn’t the same implantation methodology seen by other 
publications, the authors believe that it was adequate for a first proof of concept paper. 
An image of the implanted valve from both atrial and ventricular vantage points can be 
seen in Figure 13. 
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Figure 12.  Stentless valve developed by Gillespie and 
colleagues.  Relies on ventricular hooks for both ventricular and 
atrial fixation.  The atrial fixation method is unique to this valve, 
as the others discussed have utilized an atrial skirt or cuff [34] 
 
 
Figure 13.  Valve implanted by Gillespie and colleagues.  Shows the 
implanted valve from the atrial side (A) and the ventricular side (B) [34]. 
 
2.4 Hemodynamics in Prosthetic Valves 
The anti-coagulation therapy is needed to prevent thrombotic events in the patient.  
These events have two causes of significant in this study:  shear stress induced 
damage to red blood cells (RBCs) or contact with the material of the prosthesis.  Since 
bioprosthetic valves are the focus of this study, the second cause may be ignored:  
Bioprosthetic valves are constructed from biological tissue that should present no 
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immune response when implanted.  Thus, the focus is on shear induced damage to the 
blood components. 
Elevated levels of shear stress around the implanted valve have been shown to cause 
potential lethal damage to RBCs and potential activation of platelets.  These can lead to 
thrombus formation or a thromboembolic event, both of which have the potential to be 
fatal.  It has been shown that Reynolds shear stress (RSS) is a primary contributing 
factor to the total shear stress experienced by these blood elements.  It has been 
theorized that RSS is not indicative of the actual mechanical environment experienced 
by blood elements [35]; however, turbulent shear stress patterns in the vicinity of the 
prosthetic valve have also been said to be indicative of long term clinical efficacy [36] 
and turbulence levels are a required measure to be investigated, as seen in the 
international standard ISO 5840 for cardiovascular implants. 
Reynolds shear stress is the component of total stress that accounts for the fluctuation 
of momentum due to turbulence in fluid flow.  RSS, , can be mathematically 
represented by  
            , 
where u’ and v’ are the velocity fluctuations in the x and y direction respectively, where x 
can be considered the axial direction and y considered the transverse direction. 
The turbulence within a series of related velocity fields, and thus the RSS values, can 
be calculated by ensemble averaging multiple cardiac cycles under the same flow 
conditions.  Reynolds stresses can be thought of as the variation of a velocity field from 
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the ensemble averaged velocity field.  These velocity, and thus, momentum fluctuations 
are the cause of RSS. 
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3.1 Chapter Introduction 
Aim 1 is to assess the leaflet kinematics and flow through each of two different mitral 
valve prosthesis designs.  Particle Image Velocimetry will be used to map the flow 
through each valve at a variety of flow conditions.  These data can then be used to 
perform turbulence analysis, among other things, to determine the turbulence stresses 
that the flow experiences.  This stress has been determined to be a significant cause of 
blood and platelet damage after prosthetic valve implantation [35]. 
Another measure of valve performance is the geometric orifice area of the valve.  This is 
a measure of the maximal orifice area through which the working fluid travels during 
peak flow.  This measure will be calculated using high speed imaging in conjunction 
with image analysis software. 
3.2 Materials and Methods 
3.2.1 Valves 
The valves used in experimentation are an iteration of Avalon Medical’s Mitraseal 
canine mitral valve replacement.  This valve is currently in clinical trials and is being 
developed in conjunction with Dr. Orton at the Colorado State University Veterinary 
Hospital.  Images of these valves can be seen in Figure 14.  By design, the valves are 
implanted via a trans-apical approach and rely on an atrial cuff and ventricular tethers 
as fixation methods to keep their place in the mitral annulus.  The valves consist of a 
woven, self-expanding nitinol stent with fixed porcine pericardial leaflets sewn into the 
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stent tube.  Also sewn to the atrial cuff is waterproof membrane to prevent leakage.  
The atrialized design (seen on the left in Figure 14) has a stent body diameter of 24mm, 
a cuff diameter of 39.5mm and a total height of 20.5mm.  The non-atrialized design 
(seen on the right in Figure 14) has a stent body diameter of 24mm, a cuff diameter of 
46mm and a total height of 22mm.   
The atrialized design features a portion of the leaflets that have been atrialized which 
results in the valve of the prosthesis sitting directly inside of the native mitral annulus.  
This splits the total height of the valve stent between the left atrium and left ventricle.  
This valve design is thought to minimize LVOT obstruction and results in fewer areas for 
stagnation and subsequent 
thrombosis formation.  The 
non-atrialized design does not 
feature atrialized leaflets, 
instead the actual valve of the 
prosthesis is well below the 
native annulus and sits within 
the left ventricle.  These 
features can all be seen in the 
figure containing images of 
the valves. 
 
Figure 14. Both valve designs used during all experiments.  
On the right is the non-atrialized design and on the left is the 
atrialized design.  The atrialized portion of the leaflets of the 
atrialized design can be seen in the lower left of the image. 
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3.2.2 Left Heart Simulator 
The left heart simulator (LHS) is a flow loop that has been fabricated in house in order 
to simulate the left ventricle of the heart.  The LHS consists of the following main 
components:  fluid reservoir, acrylic block 
housing the aortic and mitral valves, linear 
actuator, compliance chamber, and resistance 
valve.  A schematic of this flow loop can be seen 
in Figure 16 and a close up of the valve 
orientation in the idealized left ventricle can be 
seen in Figure 15.  As this flow loop was 
designed to simulate the left ventricle of the 
heart, most of the components of the loop have 
an analogue in the native heart.  The fluid 
reservoir and acrylic block are the left atrium and 
left ventricle respectively with the linear actuator simulating the contraction of the left 
ventricle. 
The linear actuator operates based on input from a custom made LabVIEW VI in order 
to drive flow through the system.  Upon rearward motion of the actuator, water is pulled 
from the reservoir, through the mitral valve and into the idealized left ventricle (acrylic 
block).  With forward motion of the actuator, water is pushed through the aortic valve, 
into the compliance chamber, through the resistance valve and back into the fluid 
reservoir.   
 
 
Figure 15.  Valve orientation in the 
idealized left ventricular block.  The 
aortic valve is position above the mitral 
valve.  In this picture a mechanical 
tilting disc valve is in the aortic 
position with the atrialized valve 
design in the mitral position. 
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The compliance chamber in the LHS is an acrylic cylindrical chamber that receives fluid 
from the flow probe at its inlet and its outlet leads to the resistance valve.  The cylinder 
is sealed except for two taps at its top; one of these taps leads to a pressure gauge and 
the other to a bulb pump.  Compliance in the system is modulated by adjusting the 
amount of air in the compliance chamber:  The greater the amount of air in the 
chamber, the greater the compliance. 
The resistance valve is a simple ball valve that can be finely modulated to alter the 
amount of flow able to go through the system.  This valve is used in conjunction with the 
compliance chamber to attain proper physiologic pressure waveforms. 
During all experiments a 21mm Medtronic Hancock valve (seen in Figure 17) was used 
in the aortic position of the left ventricle block. 
 
Figure 16.  Schematic of the Left Heart Simulator (LHS). 
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3.2.2.1 Data Acquisition and Control 
The LHS is controlled via a LabVIEW VI made specifically for this purpose.  The VI 
allows the user to control the flow conditions of the LHS while reading data from 3 
pressure transducers and a flow probe.  The pressure transducers measured 
correspond to the following physiologic measurements:  Atrial Pressure, Ventricular 
Pressure and Aortic Pressure.  The flow probe is placed downstream of the aortic valve 
in order to measure flow through the aortic valve, and thus the cardiac output (CO) of 
the system. 
The raw output of pressure and flow measurements is 
recorded in units of voltage.  Each of the probes was 
calibrated and then a C++ code is used to process the 
LabVIEW output and calculate pressures in units of mmHg 
and flow in mL/second.  This code also reports relevant 
cardiac measures such as mean arterial pressure (MAP), 
regurgitant fraction (RF), cardiac output (CO) and effective 
orifice area (EOA). 
The linear actuator motion was based on a sine wave 
function.  The VI allows the user to adjust both the frequency and amplitude of this sine 
wave:  Altering these characteristics corresponds to a change in heart rate (HR) and 
stroke volume (SV) respectively.  The HR and SV along with modulating the resistance 
valve and amount of compliance can be used to attain the proper flow and pressure 
curves needed by the user.  The VI also allows for data collection of each of the three 
 
Figure 17.  A 21mm 
Medtronic Hancock tissue 
valve was used in the aortic 
position of the idealized left 




pressure sensors and the flow probe simultaneously.  A screenshot of the VI can be 
seen in Figure 18. 
3.2.3 GOA Calculation 
Unfortunately, the pressure sensors used in the LHS lack the sensitivity needed to 
determine an accurate pressure gradient across the mitral valve during diastole.  For 
this reason, it was determined to perform GOA analysis as an alternative to EOA 
measurements. 
Each valve was implanted in the LHS and experienced the following conditions:  a HR 
of 60 bpm and a CO of 5 lpm.  High speed imaging was captured using at 250 frames 
per second for each valve design using a high speed camera (Photron, San Diego, CA, 
 
Figure 18.  LabVIEW VI built to control the Left Heart Simulator (LHS).  User input fields include 
heart rate and stroke volume as seen above.  The acquire data button and output data file path 
can also be seen. 
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Model: FASTCAM 
SA3).  Using image J 
and the SIOX 
(Simple Interactive 
Object Extraction) 
plugin, the geometric 
orifice area (GOA) 
for each valve was 
extracted during 
peak diastole, GOA 
measurements were 
taken for 9 separate 
frames; this process 
was then repeated 
over three separate 
cardiac cycles.  For each frame in question, contrast was adjusted to produce a distinct 
boundary at the leaflet edge.  In this adjusted image, the boundary of the leaflet was 
traced to produce a mask of the valve orifice.  The SIOX plugin was then used to extract 
this mask and resulting surface area measured using imageJ.  A series of images 
outlining each of these steps can be seen in Figure 19, the figure progress from A being 
the raw image to D being the final mask from which the area can be calculated.  The 
mean and standard deviations were then calculated for all measurements taken for 
each valve design. 
 
Figure 19.  The process of going from a raw high speed image (A) 
to a shell (D) that can be used to geometric orifice area (GOA) of 
the valve during its open phase.  ImageJ and the plugin SIOX were 




3.2.4 Particle Image Velocimetry 
Particle image velocimetry (PIV) is an unobtrusive, indirect way to measure kinematics 
within fluid flow.  PIV analysis utilizes a combination of micro particle seeded fluid, high 
speed camera and high powered laser to visualize flow.   
The PIV system used was constructed by LaVision Inc.  A diode-pump Q-switched 
Nd:YLF laser (Photonics Industries, Bohemia, NY) was utilized to cast a thin laser sheet 
and a mirror was used to reflect this laser sheet to centrally transect each the valve 
through the idealized left ventricular block.  Raw images were captured using a high-
speed camera synchronized to the laser pulses (Photron, San Diego, CA,Model: 
FASTCAM SA3).  Double frame images were captured at a frequency of 1 kHz.  The 
double pulse laser action is used to illuminate seed particles twice within a very short 
time period to detect fluid flow with a higher resolution, in these experiments; the double 
pulse was sent 300μs apart.  The fluid was seeded with polyamide particles (Dantec 
Dynamic Inc.) with a mean diameter of 20μm. 
Velocity field data computation was done using LaVision’s DaVis flowmaster software 
and uses a 2D cross-correlation algorithm to identify shifting patterns between frames, 
resulting in a displacement vector.  Each frame is subdivided into small regions termed 
“interrogation windows.”  The DaVis software uses 2D cross-correlation to identify the 
corresponding interrogation windows between frames.  This process is what results in 
the displacement vector.  Along with the displacement vector and the time known 
between frames, it is possible to produce a velocity vector for each window.  This 
process is expanded to each entire frame, and the result is a vector field for each frame.  
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Raw images captured with the high speed camera and resulting vector field can be 
seen in Figure 20 
From this velocity field data, a custom made MatLab code was created to perform 
statistical turbulence analysis on each testing condition.  This code performed ensemble 
averaging on 50 cardiac cycles captured under the same flow conditions.  From this 
ensemble averaged vector field, the turbulent fluctuations can be extracted and thus the 
RSS values are also extracted.  The flow velocities can also be extracted from the 
averaged vector fields.  The MatLab code used to perform this operation can be seen in 
Appendix III.  
 
Figure 20.  Raw high speed image (A) and resulting vector field (B) from PIV experimentation. 
 
3.2.5 Flow Conditions 
Each valve (Non-atrialized design and atrialized design) were tested at a variety of 
conditions.  Each was tested at three different heart rates:  60 bpm, 90 bpm and 120 
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bpm.  During all of these testing, the cardiac output was maintained at 5 liters per 
minute. 
3.2.6 Statistical Analysis 
For these methods students t test was used to test statistical significant.  Measurements 
are reported as the mean ± one standard deviation. 
3.3 Results and Discussion 
3.3.1 Flow and Pressure 
Pressure and flow curves for each valve at 60 bpm and 5 lpm can be seen in Figure 21.  
Peak flow during diastole for this condition was roughly 290 mL/s for the atrialized 
design and 245 mL/s for the non-atrialized design.  Average pressure gradient across 
the mitral valve during diastole was roughly 4 mmHg for the atrialized design and 3 
mmHg for the non-atrialized design.  
Pressure and flow curves for each valve at 120 bpm and 5 lpm can be seen in Figure 
22.  Peak flow during diastole for this condition was roughly 340 mL/s for the atrialized 
design and 330 mL/s for the non-atrialized design.  Average pressure gradient across 
the mitral valve during diastole was roughly 6 mmHg for the atrialized design and 5 
mmHg for the non-atrialized design.  
The values of pressure drop across the prosthesis during diastole during these 
experiments were on the high end of acceptable.  In all likelihood, the valves perform 
acceptably, the pressure taps used in the LHS were not sensitive enough to calculate 






Figure 21.  Pressure and flow wave forms for each valve design at a heart 




































Figure 22.  Pressure and flow wave forms for each valve design 
at a heart rate of 120 beats per minute and cardiac output of 5 
liters per minute 
 
3.3.2 GOA and leaflet kinematics 
The results of the GOA calculations were 2.46±0.04 cm2 for the atrialized leaflet design 
and 2.68±0.07 cm2 for the non-atrialized design.  The difference between GOA values 
for the valve designs is statistically significant with a p-value of less than 0.001.  The 
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raw data for these calculations can be seen in Appendix I.  The outer diameter of the 
valve stents were the same when measured, the difference in GOA values appeared to 
be due to the atrialized nature of one valve design.  The portion of the valve leaflets that 
is atrialized protrudes into the orifice during diastole and during leaflet closure, this 
portion is free to bulge unrestrained.  This bulge during the high pressure closing of the 
mitral valve is an area that could produce a large amount of stress in the leaflets and 
had an adverse impact on the long term durability of the valve. 
The resulting coaptation of each valve design can be seen in Figure 23.  These images 
are indicative of all cardiac cycles for each valve and reveal proper coaptation for both 
the atrialized and non-atrialized valve designs. 
Opening times for both valves at the start of diastole were approximately 0.08 seconds 
with closing times being slightly longer at closer to 0.10 seconds. 
 
Figure 23.  High speed imaging reveals proper coaptation for both the atrialized design (A) 
and the non-atrialized design (B) 
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3.3.3 Flow and Turbulence 
Vector fields with contours representing vorticity (red and blue being opposite directions 
of out of plane vorticity) for each valve at 60bpm (Figure 25) and 120bpm (Figure 26) 
can be seen in the following figures.  In each of the figures below, the fluid flow is 
moving from left to right and the scale for the vorticity contours is identical between all 
images. 
Fluid flow through the valves begins with leaflet opening and the start of flow through 
the valve.  This results in the formation of an out of plane vortex ring.  Eventually the 
flow becomes unstable with some vortex shedding being seen before the flow begins to 
decelerate and systole begins. 
As can be seen in the figures, the vector fields and vorticity 
dynamics between the two valve designs are essentially 
indistinguishable.  Analysis of these vector fields shows 
proper vortex ring formation which is an important feature in 
the healthy heart.  During diastole, a vortex ring forms in 
the left ventricle.  A CFD model of blood flow through a 
human heart depicts this vortex formation in Figure 24 and 
is very similar to the vector fields obtained from PIV. 
The same vortex fields with contours representing 
Reynolds shear stresses (RSS), as opposed to vorticity, can be seen in Figure 27 (60 
bpm) and Figure 28 (120 bpm).  In these figures, the values of RSS are presented in 
 
Figure 24.  Computational 
vector fields resulting from 
the fluid flow through a 
healthy mitral valve during 
diastole [37]. 
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N/m2.  Accompanying these figures, a table of the maximum RSS and velocity values 
can be seen Table 1. 
Turbulent stresses ranging from 10-100 Pa have been shown to trigger platelet 
activation; however, activation is also dependent on the time in which the platelets are 
exposed to this stress.  To note, the stress needed to cause hemolysis is much higher 
than this value and is estimated at greater than 600 Pa [8].  The maximum RSS and 
velocity values seen in Table 1 are well within the safe ranges for RBC damage; 
however the valves do have the potential to cause platelet activation.   
These data cannot be compared directly to literature results due to the working fluid and 
non anatomical geometry of the left ventricular block used for testing.  It would have 
been useful to have a control mitral bioprosthesis to compare the TAMI valves to.  The 
small orifice relative to other mitral prosthesis may be a contributing factor to the high 
RSS and velocity values seen in PIV data. 
Table 1. The resulting maximum Reynolds Shear Stress (RSS) for 
each valve under a range of heart rates.  Each valve and heart rate 
was tested at a cardiac output of 5 liters per minute.  Also shown is 




Valve Heart Rate (bpm) Max RSS (N/m^2) Max Vx (m/s)
Atrialized 60 58.3 1.35
Atrialized 90 70.9 1.57
Atrialized 120 101.9 1.65
Non-Atrialized 60 45.4 1.41
Non-Atrialized 90 69.2 1.32
Non-Atrialized 120 72.5 1.62
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Figure 25.  Vorticity dynamics for each valve at a heart rate of 60 bpm 
and cardiac output of 5 lpm.  The vectors represent velocity and the 
contours represent opposite directions of out of plane vorticity.  The 




Figure 26. Vorticity dynamics for each valve at a heart rate of 120 
bpm and cardiac output of 5 lpm.  The vectors represent velocity 
and the contours represent opposite directions of out of plane 
vorticity.  The atrialized valve design is on the left and the non-




Figure 27.  Vector fields with contours representing Reynolds shear 
stress (N/m
2
) throughout diastole for a heart rate of 60bpm and 
cardiac output of 5lpm.  Atrialized valve design is on the left and the 
non-atrialized design is on the right. Images go in sequence from the 
beginning of diastole (top) to the end of diastole (bottom). 
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Figure 28.  Vector fields with contours representing Reynolds shear 
stress (N/m
2
) throughout diastole for a heart rate of 120bpm and 
cardiac output of 5lpm.  Atrialized valve design is on the left and the 
non-atrialized design is on the right.  Images go in sequence from 
the beginning of diastole (top) to the end of diastole (bottom). 
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4.1 Chapter Introduction 
Aim 2 is to evaluate and understand the differences in mechanics between two different 
methods of ventricular fixation in transapical mitral valve implantation.  In this 
experimentation, two differing methods of ventricular attachment will be assessed:  
Tethering and hooking.   As described previously, the valves used in this study were 
designed to be implanted with tethering as the primary means of ventricular fixation, so 
the designed method of implantation will be used during tethered implantation of the 
valve into the porcine test sample. 
In tethered trans-apical valve implantation, the valve’s atrial cuff and stent body are 
sequentially released into the left atrium and mitral annulus respectively.  The tethers 
are then individually tensioned and secured to the myocardial tissue of the left ventricle 
in close proximity to the apex of the heart.  The tensioning of this process is done using 
medical imaging to minimize PVL, MR, and LVOT obstruction.  Once this has been 
optimized, the tethers are secured permanently.   
For the second method of fixation, it is not an option to alter or produce new valve 
stents with hooks, so a differing method will be used to closely replicate the hooking 
method.  The valves will be sutured into place, using the same anatomical locations for 
sacrament as seen in the Tiara mitral valve developed by Neovasc, Inc. 
The primary measure of concern is paravalvular regurgitation. There are two means of 
regurgitation through prosthetic heart valves:  central regurgitation and paravalvular 
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regurgitation.  Central regurgitation occurs when the leaflets do not have proper 
coaptation and allow blood to pass in a retrograde fashion through the valve.  
Paravalvular regurgitation is when blood passes through an orifice other than that in 
which the leaflets reside.  This type of leakage is sometimes seen in standard open 
heart implanted prostheses, but is seen more often and is considered more of a 
problem with minimally invasive valves.  Minimally invasive valves typically rely on radial 
force or other means as fixation methods, whereas conventional valve replacements 
often have a suture ring directly attached to the valve.  This opens the minimally 
invasive options to paravalvular regurgitation:  Anytime there is a non-uniform 
expansion of the stent or incomplete seal of the cuff against the native tissue, there 
exists a possible orifice for PVL to occur 
Due to the anatomical constraints of the mitral valve – as discussed in a previous 
section – the valves cannot use radial force as the primary means of fixation.  Two 
alternatives to this are being investigated in the following pages. 
4.2 Aim 2 Methods 
4.2.1 In Vitro Beating Heart Simulator 
For this portion of experiments a passively beating heart simulator, known as the in-vitro 
beating heart simulator (IVBHS) was used.   The system is made up of five main 
components; a diaphragm pump, porcine test section with accompanying adapters, data 
acquisition and control, flow control and fluid reservoir.  The schematic for the IVBHS 
can be seen in Figure 29. 
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The diaphragm pump is a pneumatic design consisting of a large rigid acrylic cylinder 
with an acrylic flange on one end that allows attachment to a thin walled flexible tube.  
This flexible tube is capped on the either end to prevent any fluid leakage.  The large 
acrylic cylinder is compressed against the cylinder end and the other end of the cylinder 
is capped as well, resulting in a sealed pressure vessel.  The pressure vessel has two 
13mm holes with acrylic tubes that are connected to Tygon tubes that go to one of two 
different solenoid valves.  One solenoid valve is connected to a vacuum line while the 
other is connected to a high pressure air line.  The pressure in the air line is controlled 
using a pressure regulator that is upstream of the solenoid valve.   
 
Figure 29.  Schematic of the In Vito Beating Heart Simulator (IVBHS). 
 
Air pressure is used to create the pumping action within this diaphragm pump.  When 
the vacuum line is active, the flexible membrane expands, drawing water through the 
mitral valve and into the diaphragm pump.  The high pressure air line is then activated – 












the flexible tube and expels fluid out of the pump and back into the left ventricle of the 
porcine test section. 
The porcine test section is immersed in a tank and held in place by specifically designed 
aortic and ventricular adapters (the porcine test section and preparation is described in 
depth in its own section).  The test section is immersed for several reasons.  An early 
design iteration of this system needed passive actuation of the mitral valve, which the 
column of water above the immersed section provided.   A second reason is that 
immersion allows the entire left atrium to be removed and the mitral valve, fully 
visualized.  This allows for complete access to and view of the mitral valve; which is 
necessary for proper visualizing and placement of any mitral valve prosthesis (or repair 
device) without the need for complex medical imaging. 
Upstream of the aortic adapter and downstream of the ventricular adapter there are 
fittings that allow for the insertion of 3mm OD thin walled nylon tubing.  The end of the 
tubing has been thermally welded and 1.5 mm diameter ports are upstream at 5 mm 
increments and 90 degrees from each other.  Theses tubes lead to pressure sensors 
that allow for the real time measurement of ventricular and aortic pressure.  The tubing 
length has been measured specifically such that the pressure taps are located 3-5mm 
inside of the left ventricle and 5-10 mm downstream of the aortic valve.  The ventricular 
adapter is attached to the tube leading to the diagraph pump and the aortic adapter is 
attached to the tube leading to the flow meter, compliance chamber and resistance 
valve. 
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An in-line flow probe downstream of the aortic valve as well as a clamp-on flow probe 
upstream of the ventricular adapter allows for measuring of flow rate through the system 
without any significant pressure drops.  The inline flow probe is held in place using hose 
clamps between two pieces of tygon tubing.  The clamp-on flow probe has been design 
and calibrated to clamp onto the outside of 1 ¼ inch tygon tubing.  
The in-line flow meter is connected downstream from the compliance chamber which is 
used to simulate the compliance of the systemic cardiovascular system due to the 
flexibility of both arterial and venous walls.  The compliance chamber is an acrylic 
cylindrical chamber that receives fluid from the flow meter at its inlet and its outlet leads 
to the flow control valve.  The cylinder is sealed, except for two taps at its top; one leads 
to a pressure gauge and the other to a bulb pump.  Compliance is varied by varying the 
amount of air in it using the bulb pump:  more air in the chamber results in more 
compliance and less air results in less compliance.  The amount of compliance is 
modulated to ensure proper pressure ranges in the system to emulate physiologic 
conditions.  A simple ball valve has been placed downstream of the compliance 
chamber in order to finely modulate the amount of flow.  The ball valve can be finely 
tuned to build up proper pressures within the system and gain proper flow conditions. 
Table 2 contains detailed information about each of the flow probes and pressure 
transducers used during experimentation using the IVBHS. 
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Table 2.  Detailed information regarding flow probes and pressures sensors used during IVBHS 
experimentation. 
Item Company Model 
In-Line Flow Probe Transonic Systems, Inc (Ithica, NY) ME 25PXN 
Clamp-On Flow Probe Transonic Systems, Inc (Ithica, NY) ME 20PXL 
Flow Meter Transonic Systems, Inc (Ithica, NY)  Model T402 
2 x Pressure Sensor Validyne Engineering Corp. (Northridge, CA) DP15-34 
 
 
4.2.2 DAQ and Control 
The IVBHS is both monitored and controlled using a custom LabVIEW VI designed and 
created for this purpose.  The VI records data from both pressure transducers and one 
ultrasonic flow meter at a time (either the in-line or clamp on – but not simultaneously) 
and sends user controlled signals to the two solenoid valves that control the diaphragm 
pump. 
The VI displays – both graphically and numerically – systolic and diastolic pressures; 
mean arterial pressure; and cardiac output.  The VI allows the user to control the heart 
rate and duty cycle; the other parameters must be adjusted using the compliance 
chamber and resistance valve physically located on the IVBHS.   
The LabVIEW VI also allows the user to collect all pressure and flow data for a specified 
period.  This allows for precise measurements of pressure and flow curves for each 
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transducer.  A screen shot of LabVIEW VI showing all control and output fields can be 
seen in Figure 30. 
4.2.3 Heart Preparation 
Porcine hearts were harvested according to our specifications and were received from 
the abattoir as seen in Figure 31.  Any cuts or damage to the exterior tissue of the heart 
as a result of the harvesting process or transportation resulted in the heart being 
disposed of.  The hearts were stored in phosphate buffered saline at a temperature of 2 
– 4 ⁰C from immediately after being gathering until used in experimentation.  
 
Figure 30.  LabVIEW VI built to control the In Vitro Beating Heart Simulator (IVBHS).  User input 
fields include heart rate and duty cycle as seen above.  The VI also includes a data acquisition 
toggle button as well as graphical displays of the following:  Ventricular Pressure, Aortic 
Pressure, and Flow Rate. 
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Before experimentation, each heart was prepared in the same manner.  All extraneous 
tissue was removed.  The removed tissue included:  Any pericardium, non-cardiac 
tissue remaining attached to the heart, left and right atrium, pulmonary artery, and any 
fatty deposits on the aorta.  When removing the left atrium, enough tissue was left for 
the atrial cuff of the implanted bioprostheses to seat properly.  In some instances, the 
remaining atrial tissue would begin to occlude the opening to the mitral valve.  In these 
cases, the remaining atrial tissue was lightly pulled back and secured to outside of the 
heart using sutures.  Care was made to not affect the annulus geometry by tensioning 
the atrial tissue to a high degree.  The aorta was then trimmed, leaving approximately 
25mm of aortic tissue downstream of the aortic valve commissures and the coronary 
arteries were tied off with sutures to prevent 
any coronary flow.  Ports were inserted into the 
left ventricle and the remaining aorta in order 
to attach the heart into the IVBHS.   
The aortic adapter consisted of a thin walled-
acrylic tube.  On one end, the adapter is the 
same diameter as the Tygon tubing to which it 
was attached and the other end was 
approximately the same ID as the aorta.  
Several aortic adapters were made to 
correspond to varying aortic sizes in the 
porcine test sections.  Two nylon tie wraps are positioned next to each other along the 
axis of the adapter around the portion of the aorta with the adapter inserted in it.  The tie 
 
Figure 31.  Porcine heart as received from 
the abattoir, before extraneous tissue has 
been removed. 
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wraps are then tightened.  The larger diameter portion of the adapter is then inserted in 
the Tygon tubing and fixed into position with hose clamps.   
The ventricular adapter was of custom 
design. It has 3 main parts; a tapered 
section, a cylindrical section and a flange.  
The inside diameter of the adapter is 25.4 
mm and the length is 50.8 mm.  The two 
sections are sub-divided by the flange 
which is 38.1 mm in diameter and 1 mm 
thick.  A circular piece of polyester fabric 
approximately 76 mm with a 25 mm hole in 
the middle is fitted over the cylindrical 
portion of the adapter and held in place 
with a tie wrap.  The tapered end is 
inserted through a hole in the left ventricle 
the size of which is equal to the smallest outside diameter of the tapered section, 
approximately 26 mm.  When creating this hole in the left ventricle, the ventricular 
adapter itself is used as a ‘corer.’  A surgical blade and forceps are used to cut through 
any remaining intact myocardial tissue.  Great care is used at this point to ensure that 
the native mitral apparatus is left as undamaged as possible.  It is important to be sure 
that the native papillary muscles and chordae tendinae remain largely intact to ensure 
proper left ventricular geometry.  The adapter is then held in place against the exterior 
wall of the left ventricle using a continuous suture technique through a polyester fabric 
 
Figure 32.  Fully prepared porcine heart for 
use in the IVBHS.  Ventricular port is seen on 
the right while the aortic port is seen on the 
top of the heart. 
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ring and the exterior wall of the left ventricle.  The fabric and suture force the flange and 
taper against the tissue and seal the adapter to the heart so that minimal fluid leaks 
from the heart as the left ventricle is pressurized.  The cylindrical portion of the adapter 
is inserted into Tygon tubing coming from the diaphragm pump and held in place with a 
hose clamp.  Figure 32 shows a properly prepared porcine heart as used in 
experimentation. 
4.2.4 Valve Implantation 
Firstly, each of the 3 tethers is threaded through one of the three eyelets on the stent 
body.  The tether attachment can be seen in Figure 33.  Then a small hole 
approximately 2.5 mm in diameter was created at the apex of the heart.  This hole 
extends through the entirety of the myocardium and into the left ventricular cavity of the 
porcine heart.  Forceps were used to securely grasp all of the tethers and then advance 
them through the previously created hole at the apex of the heart.  The forceps were 
advanced carefully so as not to cause any further damage to the myocardial tissue.  
Once through the hole, the tethers were grasped using another set of forceps while the 
original set released hold of the tethers and were retreated back through the hole in the 
apex.  The stent body was then inserted into the mitral annulus by hand while the 
tethers were simultaneously tensioned to ensure proper securing of the prosthesis 
within the mitral annulus.  The tethers were then temporarily secured outside the apex 
of the heart using forceps.  
After proper implantation of the bioprosthesis, tether tension is optimized in the IVBHS.  
Real time measurement of cardiac output, tactile feel, and visualization of the prosthesis 
were used to optimize the tension.  Once a moderate cardiac output was attained in the 
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IVBHS, tether tension was modulated until PVL detected by tactile feedback using a 
gloved hand was minimized and cardiac output was maximized.  The prosthesis was 
also visualized during this procedure to ensure that the valve had not been pulled 
through the annulus and into the left ventricle.  The tethers were then secured using 
locking forceps at the apex of the heart. 
Sutured implantation begins with the preliminary placement of the attaching sutures; 
Ethicon silk 2-0 sutures were used 
for all implantations.  Three suture 
points were selected to secure each 
valve:  Two positions on the 
anterior leaflet and one on the 
posterior.   The attachment point on 
the posterior leaflet was centrally 
located on P2, while those on the 
anterior leaflet were laterally 
located at A1 and A3.  At each of 
these attachment points, a suture was looped around at least one primary chordae 
(those that attach to the free edge of the leaflet).  The suture needle was removed and 
one end of the suture was fed through each attachment points’ respective eyelet in the 
stent body.  Both free ends of the suture were pulled through the center of the valve to 
enable implant of the valve in the mitral annulus.  The valve stent body was properly 
oriented, compressed and then placed within the mitral annulus and released.  
 
Figure 33.  The orientation and attachment points of 
the tethers on the larger profile stent valve.  The 
attachment points are look identical on the valve 
design that contains more atrialized leaflets. 
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Assuming proper orientation and placement of the prosthesis, the suture associated 
with each attachment point was knotted multiple times to ensure a tight and secure fit. 
Each heart was implanted with both valve designs in the sutured fashion so great care 
had to be taken when removing an implanted valve to ensure that the chordate tendinae 
used for fixation remained unharmed.  Small surgical scissors were used to cut the knot 
at each attachment point and remove the valve. 
Figure 34 shows each valve design implanted as seen from the atrium.  These 
particular valves were implanted in the sutured fashion; however, both methods of 
implantation appear identical when viewed from the atrium.  The atrialized design can 
be seen on the right while the non-atrialized design can be seen on the left. 
 
Figure 34.  Each valve design implanted as viewed from the left atrium.  
A) Larger stent profile design with the larger atrial cuff.  B) Atrialized 
stent design with smaller cuff. 
 
4.2.5 Data Measurements and Calculations 
The annulus was measured both manually and using Doppler ultrasound.  The manual 
measurement was performed using custom made measuring devices.  The measuring 
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devices were created in increments of 1mm ranging from 18mm to 32mm.  This was 
sufficient in measuring all of the hearts that were collected.  Annular measurements 
using the ultrasound were performed on captured images at the peak opening of the 
mitral valve.  Two different annulus diameters were recorded:  septo-lateral and 
intercommissural.  Mitral annulus measurement is typically performed using a sizing 
toolset provided specifically by each manufacturer that correspond to sizes of their 
specific device; however, the septo-lateral and intercommissural measurements are two 
important measurements when determining the proper mitral valve size.  An example of 
a mitral valve sizing tool and the measurements that are made with the tool are shown 
in Figure 35.  The valve sizing tool typically corresponds to a specific size of valve or 
annuloplasty ring manufactured by the company; however, they also measure the 
intercommissural distance, total area of the mitral valve and the septo-lateral distance 
[38]. 
 
Figure 35.  An example of a mitral sizing tool used by surgeons.  The tool can 
be used to measure the intercommissural distance (A), the total area of the 
valve (B) and the septo-lateral distance (C) [38]. 
 
For each porcine heart, flow and pressure data was collected for five different 
conditions.  These conditions compromise each of the two valves in two different 
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implant methods – tethered and sutured.  In addition to these four conditions, data was 
acquired for the heart with normal function of the native valve.  For each of the five 
conditions, 20 cardiac cycles of data were collected.   Ten sequential cycles utilizing the 
in line flow probe – or aortic flow – and ten sequential cycles utilizing the clamp on flow 
probe – or total flow.  In addition to flow measurements, aortic and ventricular pressures 
waveforms were captured for each cardiac cycle.  All of these measurements are made 
at 500 Hz. 
The measurement of primary concern is the flow.  For each flow meter and each cardiac 
cycle, numerical integration was performed in Microsoft Excel to calculate the forward 
volume expelled during each cardiac cycle.  Integration of the aortic flow profile results 
in a typical stroke volume seen in cardiac mechanics:  This can be seen as the blue 
area minus the red area in Figure 36A.  Integration of the clamp on flow profile, 
however, results in a total stroke:  This can be seen as the blue area in Figure 36B.  
The difference of these two strokes is interpreted as the volume of fluid that is lost in the 
system, i.e. the amount of fluid that is expelled by the diaphragm pump, but does not 
pass through the aortic valve. 
This volume of fluid has the potential to be lost in several places:  closing mitral valve 
leakage, central mitral regurgitation, leakage through the ventricular port attachment, 
trace flow through the coronary arteries and PVL.  As seen in Aim 1, the bioprosthesis 
appear to have proper leaflet coaptation that results in no central leakage.  The 
ventricular port leakage, coronary artery flow, and closing valve leakage are assumed to 
be unchanged between conditions for a given porcine test section.  Thus, only PVL is 
responsible for changes in fluid volume loss between valve treatments for each heart.  
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In order to compare the resulting PVL changes between valve treatment groups, a 
mitral regurgitant fraction (MRF) value was calculated for each condition.  The MRF is 
equal to the mitral regurgitant volume divided by the total stroke.  The regurgitant 
volume is calculated by subtracting the forward aortic volume during systole from the 
total forward stroke.  The aortic flow during systole can be taken as the area under the 
first large peak seen in the flow waveform.  A larger MRF value indicates a worse 
performing valve than a lower MRF value:  An MRF of 1 indicates that the entire total 
forward stroke was regurgitant volume while an MRF of close to 0 would indicate a 
valve with very little regurgitant volume.  All volumes calculated from flow curves are 
based on the averaging of 10 cardiac cycles. 
During all experiments, water was used as the working fluid in the IVBHS.  In vivo, the 
working fluid flowing through the heart would be blood which has a much higher 
viscosity than water.  In order to gain a better understanding of what the mitral MRF 
would be in an in vivo environment, the MRF was scaled for the change in viscosity.  
 
Figure 36.  Flow profiles and illustration of area under the curve for aortic flow probe (A) and total 
flow probe (B).  In (A) the blue area minus the red area results in the standard stroke volume while 
the blue area in (B) corresponds to the total forward stroke. 
60 
Assuming laminar flow in relatively small regurgitant orifices, the volume scales linearly 
as compared to velocity.  The relative velocity for blood was assumed to be 3.5 for this 
scaling, thus the regurgitant volumes were divided by 3.5.  A small regurgitant orifice for 
the native condition could not be assumed because of the varying degree of 
regurgitation so it was not included in the stastical testing after the viscosity correction 
was completed. 
During IVBHS experimentation, a GE Vivid 7 Dimension ultrasound machine was used 
to perform Doppler imaging.  This imaging was used to measure maximum annulus size 
as well as to image the native and bioprosthesic valves after implantation. 
4.2.6 Statistical Analysis 
The Mann-Whitney U statistical test was used to test the statistical significance of 
values between measurements. 
Error bars in graphs and figures represent one standard deviation in either direction 
from the mean and values are represented as the mean plus or minus one standard 
deviation. 
4.3 Results and Discussion 
The raw MRF for each condition can be seen in Table 3 and Figure 37.  The data after 
the viscosity correction can be seen in Figure 38 and Table 4.  A box plot of 
consolidated MRF values from each heart can be seen in Figure 37 and data for all 
hearts can be viewed in Appendix II. 
Statistical testing produced the following results.  Lumping both conditions for the 
atrialized valve and the non-atrialized valve resulted a two-tailed p value of 0.037, 
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suggesting that the atrialized valve performs better.  The p value for non-atrialized vs. 
atrialized sutured implant was 0.047.  These p values suggest that as a whole, the 
atrialized valve performs better, but especially in sutured implantation. 
 
Figure 38.  A column plot of the mitral regurgitant fraction (MRF) for each heart and 
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Figure 37.  A column plot of the resulting mitral regurgitant fraction (MRF) for each heart 
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Statistical testing confirmed what was observed during experimentation.  With both 
implant conditions lumped for each valve design, the non-atrialized design proved 
inferior to the atrialized design.  Also, when implanted in the sutured fashion, the non-
atrialized valve design resulted in a greater amount of PVR, likely due to a poor sealing 
of the atrial cuff.  When comparing purely the tethered implantation between valve 
designs; however, the results were not statistically significant. 
 
Figure 39.  A box plot representing the viscosity corrected MRF values for each 
valve condition.  NA represents the non-atrialized valve design and A 
represents the atrialized valve design.  The native condition was left out 
because there is not a suitable viscosity correction for the condition. 
 
Relatively loose atrial fixation was noted in several cases of sutured implantation of the 
non-atrialized valve design.  It is believed that the distance from the free edge of the 














leaflet to the atrial floor is not great enough to result in a secure fit of the atrial cuff:  
Meaning that the stent height is too great for the heart in which the prosthesis was 
implanted.  Figure 44 illustrates the difference in atrial fixation during systole and 
diastole of an implanted non-atrialized valve:  Figure 44A shows a gap forming between 
the atrial skirt of the valve and the atrial floor while Figure 44B shows the same gap 
disappearing during diastole.  This same effect was not seen when implanting the non-
atrialized valve in the tethered fashion due to the ability to tension the valve manually 
instead of relying on the position of the native mitral leaflets.  It was also not observed in 
the atrialized valve design.  This is likely due to the fact that the distance from the atrial 
cuff to the fixation point of the stent is significantly less than that of the non-atrialized 
design.  This results in a much more secure fixation in the implanted hearts.  A cartoon 
of this effect can be seen in Figure 40.  When secured at the top of the stent body, as 
was done during implantation, the atrial cuff of the non-atrialized design does not secure 
well to the atrial floor while the cuff of the atrialized design does. 
Although statistical testing only confirmed one observation made during testing, several 
other parameters were determined to be important in a properly functioning TAMI valve.  
In either method of attachment, it is apparent that the combination of the stent height 
profile and ventricular fixation method together play a very important role in the function 
of the bioprosthesis.  Functional problems due to the interaction of these two 
parameters presents itself in several different fashions, these include:  LVOT 
obstruction, native leaflet interference or poor (or loose) atrial fixation.  The poor atrial 
fixation was supported by statistical testing, but the others will still be discussed below. 
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Table 4.  Results from IVBHS experiments after correcting for the viscosity difference between the working fluid and blood. 
  Heart 1 Heart 2 Heart 3 Heart 4 Heart 5 Heart 6 Heart 7 
Annulus (Intercommisural) 31 mm 24 mm 30 mm 28 mm 29 mm 28 mm 28 mm 
Annulus (anterolateral) 28 mm 24 mm 24 mm 27 mm 25 mm 26 mm 24 mm 
Native 0.73 0.74 0.51 0.85 0.53 0.59 0.29 
Non-Atrialized Design - Tether 0.19 0.20 0.25 0.20 0.20 0.16 0.12 
Non-Atrialized Design - Sutured 0.21 0.20 0.20 0.16 0.17 0.17 0.16 
Atrialized Design - Tether 0.21 0.19 0.16 0.18 0.20 0.14 0.10 
Atrialized Design - Sutured 0.21 0.13 0.00 0.15 0.13 0.16 0.11 
 
Table 3.  Tabular results from In Vitro Beating Heart Simulator (IVBHS) experiments.  The two different annulus measurements are 
displayed as well as the resulting mitral regurgitant fraction for each heart under each valve condition.  The annular measurement 
is the maximum measured for each measurement. 
  Heart 1 Heart 2 Heart 3 Heart 4 Heart 5 Heart 6 Heart 7 
Annulus (Intercommisural) 31 mm 24 mm 30 mm 28 mm 29 mm 28 mm 28 mm 
Annulus (anterolateral) 28 mm 24 mm 24 mm 27 mm 25 mm 26 mm 24 mm 
Native 0.73 0.74 0.51 0.85 0.53 0.59 0.29 
Non-Atrialized Design - Tether 0.66 0.69 0.87 0.69 0.69 0.57 0.43 
Non-Atrialized Design - Sutured 0.74 0.71 0.70 0.57 0.59 0.60 0.58 
Atrialized Design - Tether 0.74 0.66 0.55 0.62 0.69 0.50 0.34 




Figure 40.  Cartoon of atrialized vs. non-atrialized suture 
implantation.  Due to the large stent height of the non-
atrialized design, the atrial cuff does not secure properly to 
the atrial floor. 
 
LVOT obstruction was seen in heart 3 and heart 4 during tethered implantation of the 
non-atrialized valve.  It was also noted in many other hearts whose data did not appear 
in this report.  In the IVBHS, LVOT obstruction presents itself with a much higher 
diaphragm pump pressure being required to drive the same amount of flow.  An image, 
though hard to distinguish, of LVOT obstruction from the non-atrialized valve design can 
be seen in Figure 41.  Implantation of the same non-atrialized valves in the sutured 
fashion did not result in any LVOT obstruction.  During sutured implantation, the 
prosthesis position is fixed relative to the native leaflet tissue, thus during systole, the 
prosthesis is allowed to move with the native tissue to allow more space in the LVOT.  
No such cases of LVOT obstruction were documented when implanting the atrialized 
design in either tethered or sutured implantation. 
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Figure 41.  LVOT obstruction shown during systole (A) and diastole 
(B).  In both images the White arrow indicates the aortic valve and 
the Red arrow indicates the direction of the aorta.  The valve stent 
can be seen in contact with the inner wall of the left ventricle. 
 
In many cases, the native mitral leaflets extended beyond the valve stent and began to 
flap over the orifice of the prosthesis.  In some cases, the native leaflets did not 
experience any degree coaptation and thus had no effect on the bioprosthesis.  There 
were several cases in which the native leaflets maintained near full coaptation and 
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severely limited the activation of the prosthesis leaflets.  An instance of this occurring 
can be seen in Figure 42:  ‘A’ indicates the closed leaflets of the bioprosthesis and ‘B’ 
indicates the closed leaflets of the native mitral valve.  A cartoon illustrating this 
phenomenon more clearly can be seen in Figure 43.  This is a Doppler ultrasound 
image captured from heart 8 described below:  In this case, the native leaflets 
maintained full function.  This phenomenon did not result in overall deleterious effects, 
with the native leaflets maintaining full function, it is believed the prosthesis and the 
native leaflets worked in tandem to minimize the closing regurgitation experienced by 
the mitral valve.  In these cases, valve implantation typically improved the MRF of the  
heart, however the  values remained virtually unchanged between valve design and 
 
Figure 42. An occurrence of the native leaflets interfering with bioprosthesis 
function as captured by Doppler imaging.  The closed leaflets of the 
bioprosthesis are pointed out by ‘A’ and the closed leaflets of the native mitral 
valve are indicated by ‘B.’  In this view, the open area that would be the left 
atrium can be seen at the top of the image and the valves open into the left 
ventricle which would be below the image.  
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implant method. The occurrence of this phenomenon was seen less with often and to a 
less severe degree with sutured implantation.  During sutured implantation, the motion 
of the native leaflets is typically hindered by the presence of the suture wrapped around 
the CT.   
 
Figure 43.  An illustration of interference by the native mitral 
leaflets.  The top image shows both valves during diastole and 
the bottom image shows the valves during systole.  If the leaflets 
are long enough, they wrap around the top of the stent of the 
valve and begin to cover the orifice. 
 
Neither this study, nor any published literature, discusses the effects of a remodeling 
ventricle on the long term efficacy of percutaneous mitral valve implants.  Functional MR 
results from a displacement of the PM that changes the CT tethering on the MV leaflets.  
This displacement can be due to either an increase in the sphericity of the left ventricle 
or a remodeling of the ventricular walls:  This change in tethering causes poor 
coaptation of the MV leaflets and results in MR [39].  Surgical literature has shown that 
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repairing the MV in vases of functional MR can reduce the dimensions and sphericity of 
the left ventricle [39].  Assuming mitral replacement produces similar results to mitral 
replacement on the sphericity of the left ventricle, there is a potential for severe 
consequences of tethered TAMI implantation.  If the reverse remodeling of the left 
ventricle sufficiently reduces the distance between the area of tether fixation and the 
mitral annulus, then the force of ventricular fixation of the prosthesis may be 
compromised.  To date, there have been no published pre-clinical trials using a disease 
model such as this, so these effects have not been investigated.  However, it has been 
shown by several research groups, that in chronic studies involving transapical mitral 
valves, there has been a moderate amount of tissue in growth of the valve on both the 
ventricular and atrial elements [25, 33].  Figures illustrating this tissue in growth can be 
seen in Figure 10 and Figure 11 in the Literature Review section.  The fixating force of 
this tissue growth was not reported on in either of the publications, but should the tissue 
growth secure the valve into the native annulus, long term ventricular fixation would no 
longer be necessary.  Thus, depending on the length of time in which cardiac anatomy 
would be remodeled, the prosthesis may still be securely fixated within the native 
annulus. 
Functional MR also affects the size of the native mitral annulus, an increase in the 
septo-lateral distance is often seen in heart attack patients which results in poor leaflet 
coaptation.  Similar to reduction in left ventricle dimension and sphericity, medical 
therapy can also reduce the dilation of the mitral annulus [39].  This has several 
consequences on implanted TAMI valves.  Firstly, the decrease in septo-lateral distance 
of the annulus can place a larger amount of radial stress on the stent body of the valve, 
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which may have the potential of producing a fracture of the valve stent or may result in a 
crimping action of the valve stent that results in a malcoaptation of the prosthesis 
leaflets.  Reduction of annular dilation on may also result in an increased interference 
from native mitral leaflets.  This should not be a problem in TAMI implantation that 
hooks to the native leaflet tissue because the leaflets will be restrained; however, in 




Figure 44.  Poor atrial fixation of the non-atrialized valve design 
implanted in the sutured fashion.  (A) shows a gap forming between 
the atrial skirt of the valve and the atrial floor (pointed out by the 
white arrow) during high pressure systole and (B) shows that same 
gap disappearing during diastole. 
4.5 Potential Future Work 
Given the many things observed throughout the course of experimentation, there are 
several items that could be addressed as well as different areas of which to focus during 
future studies. 
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One important factor is the size of the mitral leaflets themselves:  During sutured 
(hooked) implantation, the leaflets are restrained such that they do not interfere with 
normal prosthesis function; however, during tethered implantation, the leaflets are not 
restrained and larger leaflets may interfere with valve function.  It would be an 
interesting way to optimize valve design based on fixation method by using a 
measurement of the mitral valve leaflet size and adjusting the stent height accordingly. 
The stent height would have to be optimally minimized to prevent LVOT obstruction, but 
large enough such that the native leaflets would not interfere with valve function. 
It would also be interesting to artificially induce left ventricular and annular dilation 
before implantation in order to assess the efficacy of the TAMI valves in a disease 
model.  Then study the long term effects by then artificially inducing remodeling of the 
left ventricle and annulus incrementally and observe the effects of valve efficiency. 
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5.1 Aim 1 – Summary 
The goal of aim 1 was to evaluate the leaflet kinematics and hemodynamics of the two 
TAMI valve designs.  To accomplish this, a left heart simulator was used in conjunction 
with high speed imagery and particle image velocimetry techniques.  The left heart 
simulator utilized a clear acrylic block in which the implanted mitral valve could be 
visualized.  Pressure and flow wave forms, geometric orifice area, vorticity and velocity 
dynamics, and Reynolds shear stresses were evaluated for each valve design at a 
variety of conditions. 
Both valve designs assessed showed adequate peak flows, average pressure gradients 
during diastole and filling dynamics during diastole.  The peaks flow during diastole at 
60 bpm was between 250 and 300 mL/s and average pressure gradients were below 5 
mmHg.  At the beginning of diastole proper vortex ring formation occurred in both valves 
at each heart rate.  The geometric orifice area for the atrialized valve design was 
notably less than that of the non-atrialized design; however, this is likely due to the 
atrialized nature of the leaflets and their slight impingement on the valve orifice. 
The maximum velocities and RSS levels during diastole for both valve designs were 
slightly elevated:  At 60 bpm, the maximum velocities were upwards of 1.3 m/s and RSS 
values were roughly 60 N/m2 and above.  Unfortunately there exists no control 
prosthesis for which to compare these values to.  The elevated values can be 
contributed to the low viscosity of the working fluid (water) in conjunction with the 
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relatively small orifice area of these prostheses as compared to standard mitral 
bioprostheses.  Although the valves showed elevated RSS values, they still fall within 
the safe range for red blood cell damage, but they may results in a slight amount of 
platelet activation.  Further tests with a known control valve would be needed in order to 
be certain of any platelet activation that could potential occur after implantation 
5.2 Aim 1 - Limitations 
5.2.1 Idealized Left Ventricle 
The left heart simulator utilizes an acrylic block housing the mitral and aortic valves as a 
simulation of the left ventricle.  Obviously an acrylic block lacks many of the features of 
the left ventricle, including but not limited to:  rigid housing, non-contractile, lack of 
trabeculations, and anatomically incorrect relationship of the mitral and aortic valves.  
The uniform and clear nature of the acrylic; however, is a perfect environment to 
accurately perform PIV and capture high speed imaging of the prosthetic valves.  The 
acrylic block is an ideal environment to study the fluid mechanics in the immediate 
vicinity of the prosthesis. 
5.2.2 Non Blood Analogue as Working Fluid 
The working fluid used during PIV experiments was distilled water which has a different 
viscosity from blood.  Oftentimes during in vitro experiments, a glycerine based viscosity 
and density matched solution is used an analogue for blood.  Results have shown that 
viscosity does not affect pressure drop and flow patterns and velocity profiles 
downstream do not differ between water and a blood analogue [40, 41].  In addition, 
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ISO standards for the testing of bioprosthetic heart valves indicate that it is not required 
to use a blood matched working fluid. 
5.2 Aim 2 – Summary 
The goal of aim 2 was to evaluate and understand the difference in mechanics between 
two different methods of ventricular fixation for transapical mitral valves.  The two valve 
designs were implanted in a passively beating porcine heart and the paravalvular 
regurgitation was assessed. 
Two flow probes were used to measure the total flow created by the diaphragm pump 
and the aortic flow rate to determine what amount of fluid was expelled by the pump but 
did not pass through the aortic valve.  This volume was interpreted as the mitral 
regurgitant volume.  Mitral regurgitant volume was divided by the total forward volume 
to end with a mitral regurgitant fraction or MRF.  This value is a performance index with 
large values indicating a poorly performing valves and lower values indicating a valve 
that is performing well.  In order to correct for the viscosity difference between the 
working fluid in the system (water) and the conditions in vivo, a viscosity correction was 
performed to obtain the final data. 
Statistical testing of the final data resulted several significant comparisons:  The 
atrialized valve was superior to the non-atrialized valve in sutured implantation and 
when both implant conditions were lumped together, the atrialized valve performed 
better than the non-atrialized valve.  The difference between valve designs in the 
tethered implantation method was not statistically significant. 
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Both of the significant comparisons validated what was observed during 
experimentation.  In sutured implantation, the large stent profile of the non-atrialized 
design resulted in a loosely seating atrial cuff which caused a large amount of 
paravalvular regurgitation.  In contrast, the low ventricular stent height of the atrialized 
design produced a tight sealing of the atrial cuff against the floor of the left atrium.  Due 
to its small ventricular stent height; however, the atrialized design was more susceptible 
to interference from the native valve leaflets.  The interference typically only occurred 
during tethered implantation:  When implanted in the sutured fashion, the native leaflets 
were inhibited from interfering by the anchoring sutures. 
These observations show that the importance of the relationship between ventricular 
stent height and fixation method compared with native anatomy plays an important role 
in overall prosthesis function regardless of implantation method. 
5.4 Aim 2 – Limitations 
5.4.1 Paradoxical Ventricular Motion 
The IVBHS functions by sending a pressurized slug of water into the left ventricle and 
out the aortic valve in order to simulate a beat of the heart.  Due to the high pressure 
nature of this slug, the left ventricle expands during systole.  In an in vivo environment, 
the left ventricle contracting during systole is what expels fluid out the aortic valve.  
Because of this, the tissue sample in the IVBHS actually experiences a paradoxical 
motion during the cardiac cycle:  It experiences the exact opposite of what occurs in 
vivo throughout the cardiac cycle. 
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This paradoxical motion should only have an effect on the tethered method of 
implantation, if it has any effect at all. In the sutured method, the valve is fixed relative to 
the native mitral tissue and it would not respond to any changes in the size or shape of 
the left ventricle. 
5.4.2 Porcine Model as Human Analogue 
Many research studies use the ovine model for testing heart implants; however, the 
porcine heart has a greater similarity to the human heart in both size and mitral valve 
anatomy than the ovine heart.  The porcine heart is very similar to the human heart with 
respect to the arrangement of mitral leaflets and distribution and number of chordae 
tendinae [42].  It was observed during experimentation, and noted in an in depth 
comparison of porcine and human cardiac anatomy, that the porcine heart contains a 
much thicker left ventricular wall.   In addition to a thicker wall, the porcine left ventricle 
has contains larger papillary muscles and more course ventricular trabeculations [43].  
The thick ventricular wall may be the most important distinction to note.  While the 
resulting small ventricular cavity can prove difficult for imaging and attaining proper flow 
in some cases, it does not appear to affect the performance of the implanted 
bioprosthesis.  Although some of the harvested hearts with especially small ventricular 
cavities proved difficult to prep due to the close proximity of the PM and CT to the hole 
created for the port:  This would often result in either the PM or CT to be cut during 
heart prep and having to discard the heart. 
5.4.3 Replicating In Vivo Valve Implantation 
Suturing the prosthesis into place using the native valve tissue is not an exact replica of 
a mechanical attachment to the same tissue; however, the process was replicated as 
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closely as possible.  The attachment points selected for suturing were based off of 
those seen in the Tiara valve developed by Neovasc, Inc.  It appears that the Tiara 
valve engages the native mitral leaflet using three hooking mechanisms at three 
different anatomical positions:  The first and second positions occur at approximately 
the left and right fibrous trigones, while the third is centrally located on the posterior 
leaflet.  As you can see in the section detailing valve implantation, these are the same 
anatomical positions as were chosen to be suture anchor points for the valves. 
5.4.4 Flow Probe Error 
The clamp on flow meter being used was extremely susceptible to measurement error 
due to bubble formation in the system.  Care was taken to bleed all air out of the system 
before use.  This error presented itself as a relatively large inequality in the calculated 
values of total forward stroke and the total retrograde stroke.  Any data in which there 
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Figure 45 Raw data for Heart 1  
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 114.34 12.08 82.67 0.27
Aortic_Peak 31.12 0.32 84.97 0.52
Stroke Volume 27.88 0.08
Mean Beatwise Systolic Regurg 83.21 12.07
MRF 0.73 0.13
Leakage Fraction (Aortic/Total) 0.27 0.03
Cardiac Output (L/min) 1.87 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 127.45 4.65 72.36 0.13
Aortic_Peak 43.58 0.78 84.43 0.81
Stroke Volume 36.51 0.08
Mean Beatwise Systolic Regurg 83.87 4.58
MRF 0.66 0.04
Leakage Fraction (Aortic/Total) 0.34 0.01
Cardiac Output (L/min) 2.61 0.05
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 181.11 10.56 91.39 0.83
Aortic_Peak 47.12 1.51 89.98 1.26
Stroke Volume 34.16 0.02
Mean Beatwise Systolic Regurg 133.98 10.45
MRF 0.74 0.07
Leakage Fraction (Aortic/Total) 0.26 0.02
Cardiac Output (L/min) 2.83 0.09
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 141.54 13.56 92.46 1.55
Aortic_Peak 36.72 0.80 84.24 0.87
Stroke Volume 27.83 0.05
Mean Beatwise Systolic Regurg 104.82 13.53
MRF 0.74 0.12
Leakage Fraction (Aortic/Total) 0.26 0.03
Cardiac Output (L/min) 2.20 0.05
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 162.05 1.59 85.10 0.25
Aortic_Peak 41.73 0.34 84.90 0.15
Stroke Volume 37.13 0.03
Mean Beatwise Systolic Regurg 120.32 1.56
MRF 0.74 0.01
Leakage Fraction (Aortic/Total) 0.26 0.00









Figure 46.  Raw data for Heart 2  
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 111.10 1.21 83.86 0.81
Aortic_Peak 28.78 2.27 95.15 2.11
Stroke Volume 22.13 0.05
Mean Beatwise Systolic Regurg 82.31 1.92
MRF 0.74 0.02
Leakage Fraction (Aortic/Total) 0.26 0.02
Cardiac Output (L/min) 1.73 0.14
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 132.88 5.30 102.21 3.82
Aortic_Peak 41.73 19.88 103.58 4.32
Stroke Volume 43.56 0.04
Mean Beatwise Systolic Regurg 91.15 19.16
MRF 0.69 0.15
Leakage Fraction (Aortic/Total) 0.31 0.15
Cardiac Output (L/min) 2.50 1.19
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 137.07 1.11 99.58 0.10
Aortic_Peak 39.74 0.27 96.39 0.21
Stroke Volume 36.13 0.02
Mean Beatwise Systolic Regurg 97.33 1.08
MRF 0.71 0.01
Leakage Fraction (Aortic/Total) 0.29 0.00
Cardiac Output (L/min) 2.38 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 116.34 2.11 97.69 0.24
Aortic_Peak 39.89 0.81 95.43 0.54
Stroke Volume 37.12 0.08
Mean Beatwise Systolic Regurg 76.45 1.95
MRF 0.66 0.02
Leakage Fraction (Aortic/Total) 0.34 0.01
Cardiac Output (L/min) 2.39 0.05
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 75.86 0.29 99.56 0.12
Aortic_Peak 41.46 0.32 98.87 0.07
Stroke Volume 37.06 0.01
Mean Beatwise Systolic Regurg 34.40 0.14
MRF 0.45 0.00
Leakage Fraction (Aortic/Total) 0.55 0.00









Figure 47.  Raw data for Heart 3 
  
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 118.83 3.07 100.68 0.08
Aortic_Peak 58.24 0.34 101.31 0.14
Stroke Volume 56.06 0.00
Mean Beatwise Systolic Regurg 60.58 3.05
MRF 0.51 0.03
Leakage Fraction (Aortic/Total) 0.49 0.01
Cardiac Output (L/min) 3.49 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 78.77 0.91 112.98 0.17
Aortic_Peak 10.05 0.15 104.48 1.03
Stroke Volume 2.23 0.03
Mean Beatwise Systolic Regurg 68.73 0.90
MRF 0.87 0.02
Leakage Fraction (Aortic/Total) 0.13 0.00
Cardiac Output (L/min) 0.60 0.01
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 193.87 2.80 96.28 0.13
Aortic_Peak 58.70 0.47 97.47 0.21
Stroke Volume 55.00 0.06
Mean Beatwise Systolic Regurg 135.17 2.76
MRF 0.70 0.02
Leakage Fraction (Aortic/Total) 0.30 0.01
Cardiac Output (L/min) 3.52 0.03
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 130.63 1.33 96.65 0.08
Aortic_Peak 58.60 0.58 97.39 0.10
Stroke Volume 56.57 0.02
Mean Beatwise Systolic Regurg 72.03 1.19
MRF 0.55 0.01
Leakage Fraction (Aortic/Total) 0.45 0.01








Figure 48.  Raw data for Heart 4  
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 126.60 2.21 96.77 3.33
Aortic_Peak 19.29 0.33 79.13 0.22
Stroke Volume 15.07 0.04
Mean Beatwise Systolic Regurg 107.31 2.18
MRF 0.85 0.02
Leakage Fraction (Aortic/Total) 0.15 0.00
Cardiac Output (L/min) 1.16 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 145.99 1.21 -14.35 0.00
Aortic_Peak 45.54 0.34 -14.35 0.00
Stroke Volume 42.82 0.02
Mean Beatwise Systolic Regurg 100.45 1.17
MRF 0.69 0.01
Leakage Fraction (Aortic/Total) 0.31 0.00
Cardiac Output (L/min) 2.73 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 108.63 0.99 98.90 0.12
Aortic_Peak 47.03 0.56 98.26 0.11
Stroke Volume 40.80 0.01
Mean Beatwise Systolic Regurg 61.60 0.82
MRF 0.57 0.01
Leakage Fraction (Aortic/Total) 0.43 0.01
Cardiac Output (L/min) 2.82 0.03
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 119.51 1.19 93.53 2.95
Aortic_Peak 45.82 6.43 99.25 2.50
Stroke Volume 47.18 0.05
Mean Beatwise Systolic Regurg 73.69 6.32
MRF 0.62 0.05
Leakage Fraction (Aortic/Total) 0.38 0.05
Cardiac Output (L/min) 2.75 0.39
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 98.12 0.72 95.25 0.26
Aortic_Peak 44.97 0.51 95.86 0.19
Stroke Volume 41.03 0.02
Mean Beatwise Systolic Regurg 53.15 0.51
MRF 0.54 0.01
Leakage Fraction (Aortic/Total) 0.46 0.01









Figure 49.  Raw data for Heart 5  
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 114.52 2.08 85.73 0.64
Aortic_Peak 53.60 0.91 88.13 1.16
Stroke Volume 49.88 0.02
Mean Beatwise Systolic Regurg 60.93 1.87
MRF 0.53 0.02
Leakage Fraction (Aortic/Total) 0.47 0.01
Cardiac Output (L/min) 3.22 0.05
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 145.99 1.21 -14.35 0.00
Aortic_Peak 45.54 0.34 -14.35 0.00
Stroke Volume 42.82 0.02
Mean Beatwise Systolic Regurg 100.45 1.17
MRF 0.69 0.01
Leakage Fraction (Aortic/Total) 0.31 0.00
Cardiac Output (L/min) 2.73 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 126.20 2.09 98.19 0.09
Aortic_Peak 52.02 0.39 98.19 0.10
Stroke Volume 49.13 0.01
Mean Beatwise Systolic Regurg 74.18 2.05
MRF 0.59 0.02
Leakage Fraction (Aortic/Total) 0.41 0.01
Cardiac Output (L/min) 3.12 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 154.56 4.65 94.52 1.81
Aortic_Peak 47.55 2.77 96.06 2.09
Stroke Volume 39.41 0.11
Mean Beatwise Systolic Regurg 107.01 3.74
MRF 0.69 0.03
Leakage Fraction (Aortic/Total) 0.31 0.02
Cardiac Output (L/min) 2.85 0.17
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 95.35 0.80 90.54 0.09
Aortic_Peak 51.25 0.58 90.66 0.10
Stroke Volume 48.30 0.03
Mean Beatwise Systolic Regurg 44.10 0.55
MRF 0.46 0.01
Leakage Fraction (Aortic/Total) 0.54 0.01









Figure 50.  Raw data for Heart 6 
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 134.29 2.54 111.65 0.42
Aortic_Peak 54.48 0.31 105.17 0.89
Stroke Volume 50.04 0.02
Mean Beatwise Systolic Regurg 79.82 2.52
MRF 0.59 0.02
Leakage Fraction (Aortic/Total) 0.41 0.01
Cardiac Output (L/min) 3.27 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 123.66 2.62 101.61 0.81
Aortic_Peak 53.54 0.34 101.80 0.36
Stroke Volume 48.46 0.07
Mean Beatwise Systolic Regurg 70.12 2.60
MRF 0.57 0.02
Leakage Fraction (Aortic/Total) 0.43 0.01
Cardiac Output (L/min) 3.21 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 137.20 3.62 102.05 0.14
Aortic_Peak 54.28 0.38 98.88 0.15
Stroke Volume 48.43 0.08
Mean Beatwise Systolic Regurg 82.91 3.60
MRF 0.60 0.03
Leakage Fraction (Aortic/Total) 0.40 0.01
Cardiac Output (L/min) 3.26 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 113.71 6.88 106.40 0.18
Aortic_Peak 56.57 0.63 105.47 0.19
Stroke Volume 51.65 0.03
Mean Beatwise Systolic Regurg 57.14 6.86
MRF 0.50 0.07
Leakage Fraction (Aortic/Total) 0.50 0.03
Cardiac Output (L/min) 3.39 0.04
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 132.26 3.37 96.81 0.19
Aortic_Peak 56.22 0.34 97.23 0.06
Stroke Volume 50.56 0.05
Mean Beatwise Systolic Regurg 76.04 3.35
MRF 0.57 0.03
Leakage Fraction (Aortic/Total) 0.43 0.01









Figure 51.  Raw data for Heart 7. 
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 79.49 0.31 100.71 0.31
Aortic_Peak 56.79 0.45 100.02 0.31
Stroke Volume 52.80 0.08
Mean Beatwise Systolic Regurg 22.70 0.32
MRF 0.29 0.00
Leakage Fraction (Aortic/Total) 0.71 0.01
Cardiac Output (L/min) 3.41 0.03
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 94.88 0.85 116.18 0.63
Aortic_Peak 54.30 0.74 109.37 0.75
Stroke Volume 51.48 0.02
Mean Beatwise Systolic Regurg 40.57 0.41
MRF 0.43 0.01
Leakage Fraction (Aortic/Total) 0.57 0.01
Cardiac Output (L/min) 3.26 0.04
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 133.58 2.08 101.26 0.30
Aortic_Peak 56.52 0.34 100.95 0.18
Stroke Volume 51.35 0.01
Mean Beatwise Systolic Regurg 77.07 2.05
MRF 0.58 0.02
Leakage Fraction (Aortic/Total) 0.42 0.01
Cardiac Output (L/min) 3.39 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 84.82 1.79 103.91 0.10
Aortic_Peak 55.78 0.35 102.43 0.19
Stroke Volume 51.31 0.04
Mean Beatwise Systolic Regurg 29.05 1.75
MRF 0.34 0.02
Leakage Fraction (Aortic/Total) 0.66 0.01
Cardiac Output (L/min) 3.35 0.02
Mean Systolic Stroke (mL) St Dev MAP St Dev
Total 87.68 0.73 102.98 0.06
Aortic_Peak 55.26 0.34 102.51 0.12
Stroke Volume 52.17 0.03
Mean Beatwise Systolic Regurg 32.42 0.64
MRF 0.37 0.01
Leakage Fraction (Aortic/Total) 0.63 0.01












%Goes through the specified number of B files, where B number format is:  
%B00001. Calls VelOut function, which loadvecs all files within B file... 
%B00001_01, etc. Then that function outputs a average vector fileish. 
  
%Specify how many B Numbers to go through: 
numBN=261; 
  
%Go through each B number: 
for BN=1:1:numBN 
    
    %Converts number to string with 0s in front with a total of numPlaces 
    %places 
     
    %Initialize numStr: 
    BNS='B00000'; 
  
    %Convert num to string: 
    ns=mat2str(BN); 
     
    %Get the number of characters in the number 
    numChar=size(ns,2); 
     
    BNS(end-numChar+1:end)=ns; 
     










% This program will calculate the mean of Vx' and Vy' and print a dat file 
% from which contours plot can be drawn easily 
  
  




image = q1;  
  
  
%% Reading the Vx and Vy data and making mean & Standard deviation of velocity  
  
for q=1:1:128 % (changed 256-128) reading the data of every point and making mean 
and std 
    for p=1:1:128 % changed 124-128 
        for i=1:1:image 
            velox(i)=v(1,i).vx(q,p); 
            veloy(i)=v(1,i).vy(q,p); 
        end; 
        meanx(q,p)=mean(velox); 
        meany(q,p)=mean(veloy); 
         
        stdx(q,p)=std(velox); 
        stdy(q,p)=std(veloy); 










%% Data Truncation 
for i=1:1:image   
    velox=v(1,i).vx(:,:); 
    outlierx=abs(velox-meanx) > 3*stdx; 
    outlierx_sum=outlierx+preoutlierx;% getting a matix where the outliers are 
    preoutlierx=outlierx_sum;% Summing them at all images 
101 
     
    fvelox=velox.*~outlierx; % negelecting the outliers from the sums 
    fvelox_sum=fvelox+prevelox; 
    prevelox=fvelox_sum; 
    v2(1,i).velox(:,:)=fvelox(:,:); 
     
    veloy=v(1,i).vy(:,:); 
    outliery=abs(veloy-meany) > 3*stdy; 
    outliery_sum=outliery+preoutliery;% getting a matix where the outliers are 
    preoutliery=outliery_sum;% Summing them at all images 
     
    fveloy=veloy.*~outliery; % negelecting the outliers from the sums 
    fveloy_sum=fveloy+preveloy; 
    preveloy=fveloy_sum; 
    v2(1,i).veloy(:,:)=fveloy(:,:); 
end; 
  
meanvelox=fvelox_sum./(image-outlierx_sum); % new mean after removing outliers 
meanveloy=fveloy_sum./(image-outliery_sum); 
  
%% Subtracting mean velocity from instantenous velocity square them and 
%% again making them mean  
for i=1:1:image 
    veloxx=v2(1,i).velox(:,:);  
    invelox=(veloxx-meanvelox); 
    invelox1=invelox.*invelox; 
    suminvelox1=presuminvelox1+invelox1; 
    presuminvelox1=suminvelox1; 
     
    veloyy=v2(1,i).veloy(:,:);  
    inveloy=(veloyy-meanveloy); 
    inveloy1=inveloy.*inveloy; 
    suminveloy1=presuminveloy1+inveloy1; 
    presuminveloy1=suminveloy1; 
     
    inveloxy=invelox.*inveloy; % for Vx'Vy' 
    suminveloxy=presuminveloxy+inveloxy; 
    presuminveloxy=suminveloxy; 
end;  
  








secmeanxy=suminveloxy./(image-(outlierx_sum+outliery_sum)); % for Vx'Vy' 
  
%% taking x position and y position which will be used to print the file  






%% Printing file 
textfilename=['VelOut_Output' '_B' mat2str(BNum) '.dat']; % Writing the file and storing 
data in it 
fid=fopen(textfilename, 'wt'); 
          
        fprintf (fid,... 
            'VARIABLES = "X position","Y 
position","Vx","Vy","Vxdash","Vydash","VxVydash"\n'... 
            ); % writing the column header 
        fprintf (fid,'ZONE T="Frame 01", I= %02d, J=%02d\n',nx,ny); 
        for p=128:-1:1; %changed! 
            for q=1:1:128; %changed! 
             fprintf(fid,'%8.4f\t%8.4f\t%8.4e\t%8.4e\t%8.4e\t%8.4e\t%8.4e\t\n',... 
                        xpos(1,q), ypos(1,p),meanvelox(q,p),meanveloy(q,p),... 
                        veldashx(q,p),veldashy(q,p),secmeanxy(q,p)); 
            end; 
        end; 










LVOT – Left Ventricular Outflow Tract 
TAMI – Trans Apical Mitral Implantation 
TAVI – Transcatheter Aortic Valve Implantation 
PVL – Paravalvular Leakage 
PVR – Paravalvular Regurgitation 
MR – Mitral Regurgitation 
MAP – Mean Arterial Pressure 
PIV – Particle Image Velocimetry  
MV – Mitral Valve 
CT – Chordae Tendinae 
PM – Papillary Muscle 
SAM – Systolic Anterior Motion 
LF – Leakage Fraction 
GOA – Geometric Orifice Area 
mmHg – Millimeters of Mercury 
mL – Milliliters 
RSS – Reynolds Shear Stress 
RBCs – Red Blood Cells 
 
